<SEC-DOCUMENT>0001144204-14-044921.txt : 20140725
<SEC-HEADER>0001144204-14-044921.hdr.sgml : 20140725
<ACCEPTANCE-DATETIME>20140725142853
ACCESSION NUMBER:		0001144204-14-044921
CONFORMED SUBMISSION TYPE:	F-10
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20140725
DATE AS OF CHANGE:		20140725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-10
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-197633
		FILM NUMBER:		14993921

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-10
<SEQUENCE>1
<FILENAME>v384723_f10.htm
<DESCRIPTION>FORM F-10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the Securities and Exchange
Commission on July 25, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration Statement No. 333-&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED
STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1pt solid; text-align: center">

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><B>FORM F-10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 77px; width: 355px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt">ONCOLYTICS
BIOTECH INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 32%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Alberta</b></font></td>
    <td style="width: 3%; text-align: center">&nbsp;</td>
    <td style="width: 31%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2834</b></font></td>
    <td style="width: 3%; text-align: center">&nbsp;</td>
    <td style="width: 31%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Not Applicable</b></font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">(Province or other jurisdiction of</font><br>
<font style="font-size: 10pt">incorporation or organization )</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">(Primary Standard Industrial</font><br>
<font style="font-size: 10pt">Classification Code Number)</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">(I.R.S. Employer Identification No.)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><B><BR>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite #210, 1167 Kensington Crescent
N.W.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calgary, Alberta</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Canada T2N 1X7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(403) 670-7377</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address and Telephone number of Registrant&rsquo;s
Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>C T Corporation System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>111 Eighth Avenue, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10011, U.S.A.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>(212)
590-9070</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Name, Address (including
zip code) and Telephone Number (including Area Code) of Agent for Service in the United States)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Kenneth G. Sam, Esq.</i></b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Jason K. Brenkert, Esq.</i></b><i><br>
        Dorsey &amp; Whitney LLP<br>
        1400 Wewatta Street, Suite 400<br>
        Denver, CO 80202-5549</i></P></td>
    <td style="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Kirk Look<br>
        Suite #210, 1167 Kensington Crescent N.W.</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Calgary, Alberta</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Canada T2N 1X7</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(403) 670-7377</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&nbsp;</i></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of proposed sale to
the public</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">From time to time after the effective date
of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Province
of Alberta, Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal jurisdiction regulating this
offering)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is proposed that this filing shall become
effective (check appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 2%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">A.</font></td>
    <td style="width: 1%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 3%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="width: 94%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada).</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">B.</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font: 10pt Wingdings">x</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">At some future date (check the appropriate box below):</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 4%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">1.</font></td>
    <td style="width: 1%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 4%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="width: 84%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">pursuant to Rule 467(b) on __(date) at___(time) (designate a time not&nbsp;&nbsp;sooner than 7 calendar days after filing).</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">2.</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">pursuant to Rule 467(b) on __(date) at ___(time) (designate a time 7 calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ___(date).</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">3.</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">4.</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font: 10pt Wingdings">x</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">after the filing of the next amendment to this Form (if preliminary material is being filed).</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction&rsquo;s shelf prospectus offering
procedures, check the following box. <FONT STYLE="font-family: Wingdings">x</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="4" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="25" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>CALCULATION OF REGISTRATION FEE</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="25" style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="image_002.gif" alt="" style="height: 2px; width: 100%"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>Title of each class of</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="9" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>Proposed maximum</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>Amount of</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>securities to be registered</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="9" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>aggregate offering price (1) (2) </b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>registration fee</b></font></td></tr>
<tr>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_003.gif" alt="" style="height: 2px; width: 147px"></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="9" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_004.gif" alt="" style="height: 2px; width: 126px"></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_004.gif" alt="" style="height: 2px; width: 126px"></td></tr>
<TR>
    <TD COLSPAN="7" STYLE="padding-right: 1.75pt; padding-left: 1.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="padding-right: 1.75pt; padding-left: 1.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="padding-right: 1.75pt; padding-left: 1.75pt">&nbsp;</TD></TR>
<tr>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Shares, Subscription Receipts, Warrants,
        and Units<sup>(3)</sup></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="9" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt">U.S.$139,650,000</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt">U.S.$17,987</font></td></tr>
<tr>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_003.gif" alt="" style="height: 2px; width: 147px"></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="9" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_004.gif" alt="" style="height: 2px; width: 126px"></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="7" style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><img src="image_004.gif" alt="" style="height: 2px; width: 126px"></td></tr>
<tr>
    <td colspan="7" style="border-bottom: Black 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>TOTAL</b></font></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt">U.S.$139,650,000</font></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt; text-align: center">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt">U.S.$17,987</font></td></tr>
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: right">&nbsp;</td>
    <td colspan="20" style="vertical-align: bottom; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">(1)</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: right"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="20" style="vertical-align: bottom; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Rule 457(o) permits the registration fee to be calculated on the basis of the maximum offering price of all of the securities listed and, therefore, the table does not specify by each class information as to the amount to be registered or the proposed maximum offer price per security.&nbsp;&nbsp;The proposed maximum initial offering price per security will be determined, from time to time, by the Registrant.&nbsp;&nbsp;In no event will the aggregate initial offering price of all securities issued from time to time pursuant to this Registration Statement exceed U.S.$139,650,000.</font></td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; padding-top: 3pt; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">(2)</font></td>
    <td style="vertical-align: top; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td colspan="20" style="vertical-align: top; padding-top: 5pt; padding-bottom: 5pt; text-align: justify"><font style="font-size: 10pt">Determined based on the proposed maximum aggregate offering price in Canadian dollars of Cdn$150,000,000 converted into U.S. dollars based on the noon rate of exchange on July 23, 2014, as reported by the Bank of Canada, for the conversion of Canadian dollars into U.S. dollars of Cdn$1.00 equals U.S.$0.931.</font></td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; padding-top: 3pt; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">(3)</font></td>
    <td style="vertical-align: top; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td colspan="20" style="vertical-align: top; padding-top: 5pt; padding-bottom: 5pt; text-align: justify"><font style="font-size: 10pt">Subject to footnote (1), there are being registered hereunder an indeterminate number of Common Shares, Warrants to Purchase Common Shares or Subscription Receipts, Subscription Receipts which entitle the holder to receive upon satisfaction of certain release conditions, for no additional consideration, Common Shares, Warrants or any combination thereof, or Units consisting of two or more of the foregoing or any combination thereof, as may be sold from time to time by the Registrant.&nbsp;&nbsp;There are also being registered hereunder an indeterminate number of Common Shares as may be issuable upon exercise of Warrants to Purchase Common Shares or as part of Subscription Receipts or Units and such indeterminate number of Common Shares as may be issuable pursuant to anti-dilution or other similar adjustment provisions in the Warrants or Subscription Receipts.&nbsp;&nbsp;</font></td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="width: 9%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 4%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 26%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registration statement shall become effective
as provided in Rule 467 under the Securities Act, or on such date as the Commission, acting pursuant to Section 8(a) of the Securities
Act, may determine.</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED TO BE DELIVERED
TO OFFEREES OR PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red; ">&nbsp;</P>

<DIV STYLE="padding: 0.1in; text-align: center; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>Information contained herein
is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States
Securities Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration
statement becomes effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any state of the United States in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such state of the United States.</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION, DATED
JULY 25, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PRELIMINARY BASE SHELF PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_005.gif" ALT="" STYLE="height: 85px; width: 352px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Cdn.$150,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares<BR>
Subscription Receipts<BR>
Warrants<BR>
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time to time during the 25-month
period that this prospectus (the&nbsp;&ldquo;<B>Prospectus</B>&rdquo;), including any amendments, remains valid, sell under this
Prospectus up to Cdn.&nbsp;$150,000,000 (or the equivalent in other currencies or currency units) in one or more offerings, aggregate
initial offering price of our common shares (&ldquo;<B>Common Shares</B>&rdquo;), subscription receipts (&ldquo;<B>Subscription
Receipts</B>&rdquo;), warrants to purchase Common Shares (&ldquo;<B>Warrants</B>&rdquo;) and/or units comprised of one or more
of the other securities described in this Prospectus in any combination, (&ldquo;<B>Units</B>&rdquo; and, together with the Common
Shares, Subscription Receipts and Warrants, the&nbsp;&ldquo;<B>Securities</B>&rdquo;). We may offer Securities in such amounts
and, in the case of the Subscription Receipts, Warrants and Units, with such terms, as we may determine in light of market conditions.
We may sell the Subscription Receipts and Warrants in one or more series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective purchasers should note that
we are a development stage entity and that an investment in the Securities should be considered highly speculative due to various
risk factors listed under the heading &ldquo;<I>Risk Factors</I>&rdquo; on pages&nbsp;8 to 17 of the Corporation&rsquo;s AIF (as
defined herein). Prospective investors should carefully review these risk factors prior to investing in the Securities of the Corporation.
In particular, prospective purchasers should note the following risks namely, all of our potential products, including REOLYSIN&reg;,
are in the research and development stage and will require further development and testing before they can be marketed commercially;
any failure or delay in clinical trials for our products, including REOLYSIN&reg;, may cause us to incur additional costs or delay
or prevent the commercialization of our products and could severely harm our business; pharmaceutical products are subject to intense
regulatory approval processes; we have limited manufacturing experience and intend to rely on third parties to commercially manufacture
our products, if and when developed; and we have no operating revenues and a history of losses. For detailed description of &ldquo;<I>Risk
Factors</I>&rdquo; see page&nbsp;9 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific variable terms of any offering
of Securities will be set forth in a supplement to this Prospectus relating to such Securities (each, a&nbsp;&ldquo;<B>Prospectus
Supplement</B>&rdquo;) including where applicable: (i)&nbsp;in the case of the Common Shares, the number of Common Shares offered,
the currency (which may be Canadian dollars or any other currency), the issue price and any other specific terms; (ii)&nbsp;in
the case of Subscription Receipts, the number of Subscription Receipts offered, the currency (which may be Canadian dollars or
any other currency), the issue price, the terms and procedures for the exchange of the Subscription Receipts and any other specific
terms; (iii)&nbsp;in the case of Warrants, the designation, the number of Warrants offered, the currency (which may be Canadian
dollars or any other currency), number of Common Shares that may be acquired upon exercise of the Warrants, the exercise price,
dates and periods of exercise, adjustment procedures and any other specific terms; and (iv)&nbsp;in the case of Units, the designation,
the number of Units offered, the offering price, the currency (which may be Canadian dollars or any other currency), terms of the
Units and of the securities comprising the Units and any other specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are permitted, as a foreign issuer
in the United States, under a multi-jurisdictional disclosure system adopted by the United States and Canada (&ldquo;MJDS&rdquo;),
to prepare this Prospectus in accordance with Canadian disclosure requirements. You should be aware that such requirements are
different from those of the United States. We have prepared our financial statements incorporated herein by reference in accordance
with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board
and adopted by the Accounting Standards Board of Canada and they are subject to Canadian auditing and auditor independence standards
in addition to the standards of the Public Company Accounting Oversight Board (United States) and the United States Securities
and Exchange Commission (&ldquo;SEC&rdquo;) independence standards. Therefore, they may not be comparable to the financial statements
of United States companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should be aware that the purchase
of the Securities described herein may have tax consequences both in the United States and Canada. Such consequences for investors
who are resident in, or citizens of, the United States may not be described fully herein. You should read the tax discussion contained
in the applicable Prospectus Supplement with respect to a particular offering of securities. See &ldquo;<I>Certain Income Tax Considerations</I>&rdquo;
at page&nbsp;14 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Your ability to enforce civil liabilities
under United States federal securities laws may be affected adversely by the fact that we are incorporated under the laws of Canada,
the majority of our officers and directors and some of the experts named in this Prospectus are residents of Canada, and a substantial
portion of our assets and the assets of said persons are located outside the United States. See &ldquo;<I>Enforceability of Civil
Liabilities</I>&rdquo; at page&nbsp;6 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY, OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shelf information permitted under applicable
laws to be omitted from this Prospectus will be contained in one or more Prospectus Supplements that will be delivered to purchasers
together with this Prospectus. Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes
of securities legislation as of the date of the Prospectus Supplement and only for the purposes of the distribution of the Securities
to which the Prospectus Supplement pertains. You should read this Prospectus and any applicable Prospectus Supplement before you
invest in the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding securities are listed for
trading on the Toronto Stock Exchange under the trading symbol &ldquo;<B>ONC</B>&rdquo; and on the NASDAQ Capital Market under
the trading symbol &ldquo;<B>ONCY</B>&rdquo;. Unless otherwise specified in any applicable Prospectus Supplement, the Subscription
Receipts, Warrants and Units will not be listed on any securities exchange. <B>There is no market through which the Subscription
Receipts, Warrants or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased
under this Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability
of trading prices, the liquidity of the securities, and the extent of issuer regulation. See the &ldquo;Risk Factors&rdquo; section
of the applicable Prospectus Supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
underwriters, dealers, placement agents or other intermediaries or directly to purchasers or through agents. See detailed discussion
on &ldquo;<I>Plan of Distribution</I>&rdquo; at page&nbsp;13 of this Prospectus. The Prospectus Supplement relating to a particular
offering of Securities will identify each person who may be deemed to be an underwriter with respect to such offering and will
set forth the terms of the offering of such Securities, including, to the extent applicable, the initial public offering price,
the proceeds that we will receive, the underwriting discounts or commissions and any other discounts or concessions to be allowed
or re-allowed to dealers. The lead underwriter or underwriters with respect to Securities sold to or through underwriters, if any,
will be named in the related Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable securities legislation,
in connection with any offering of Securities under this Prospectus, the underwriters, if any, may over-allot or effect transactions
which stabilize or maintain the market price of the Securities offered at a level above that which might otherwise prevail in the
open market. These transactions, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this Prospectus. We have not authorized anyone to provide you with information different from that contained in this
Prospectus. No underwriters have been involved in the preparation of this Prospectus or performed any review of the contents of
this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
3700<B>, </B>400&nbsp;&ndash;&nbsp;3<SUP>rd</SUP> Avenue S.W., Calgary, Alberta, T2P&nbsp;4H2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS AND OTHER MATTERS</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE CORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OUR BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SHARE CAPITAL</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRIOR SALES</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TRADING PRICE AND VOLUME</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SUBSCRIPTION RECEIPTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTAIN INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AUDITOR</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">REGISTRAR AND TRANSFER AGENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DOCUMENTS INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001" TITLE="about"></A><B>ABOUT THIS PROSPECTUS AND OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and any Prospectus Supplement,
unless otherwise indicated, references to &ldquo;<B>we</B>&rdquo;, &ldquo;<B>us</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>issuer</B>&rdquo;
&ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo; are to Oncolytics Biotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and in any Prospectus
Supplement, unless otherwise specified or the context otherwise requires, all references to &ldquo;<B>dollars</B>&rdquo;, &ldquo;<B>Cdn.$</B>&rdquo;
or &ldquo;<B>$</B>&rdquo; are to Canadian dollars and all references to &ldquo;<B>US$</B>&rdquo; are to United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this Prospectus and any Prospectus Supplement is determined using International
Financial Reporting Standards as issued by the International Accounting Standards Board and adopted by the Accounting Standards
Board of Canada (&ldquo;<B>IFRS</B>&rdquo;). Our financial statements incorporated by reference in this Prospectus and any Prospectus
Supplement and in the documents incorporated by reference herein and therein may not be comparable to financial statements prepared
in accordance with United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus provides you with a general
description of the Securities that the Corporation may offer. Each time the Corporation sells Securities under this Prospectus,
the Corporation will provide a Prospectus Supplement that will contain specific information about the terms of that offering of
Securities. The Prospectus Supplement also may add, update or change information contained in this Prospectus. Before investing,
investors should read both this Prospectus and any applicable Prospectus Supplement together with additional information described
under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The Corporation has not authorized
anyone to provide you with different or additional information. The Corporation is not making an offer of these Securities in any
jurisdiction where the offer is not permitted by law. You should not assume that the information contained in or incorporated by
reference in this Prospectus or any applicable Prospectus Supplement is accurate as of any date other than the date of the applicable
document.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002" TITLE="special"></A>SPECIAL NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus contains certain statements
relating to future events or the Corporation&rsquo;s future performance which constitute forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or
achievements of the Corporation, or industry results, to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts,
and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations
with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future
operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related
to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or
strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified
by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo; and similar expressions, or that events or conditions &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo; occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control,
including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to all of our products,
including REOLYSIN&reg;, being in the research and development stage and requiring further development and testing before they
can be marketed commercially;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks inherent in pharmaceutical research
and development;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to timing and possible delays
in our clinical trials; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to some of our clinical
trials being conducted in, and subject to the laws of foreign countries;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our pharmaceutical products
being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to being subject to government
manufacturing and testing regulations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the extremely competitive
biotechnology industry and our competition with larger companies with greater resources;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on patents
and proprietary rights to protect our technology;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to potential products liability
claims;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our limited manufacturing
experience and reliance on third parties to commercially manufacture our products, if and when developed;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our new products not
being accepted by the medical community or consumers;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our technologies becoming
obsolete;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on third
party relationships for research and clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our lack of operating
revenues and history of losses;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainty regarding our ability to obtain
third-party reimbursement for the costs of our product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to other third-party arrangements;
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our ability to obtain
additional financing to fund future research and development of our products and to meet ongoing capital requirements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to potential increases in
the cost of director and officer liability insurance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on key
employees and collaborators;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to Barbados law;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the effect of changes
in the law on our corporate structure;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to expenses in foreign currencies
and our exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our compliance with the
Sarbanes-Oxley Act of 2002, as amended;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our status as a foreign
private issuer;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to possible &ldquo;passive
foreign investment company&rdquo; status;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to fluctuations in interest
rates; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our common shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Company&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF (as defined
below). If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results
may vary materially from those expected, estimated or projected. Forward-looking statements in this document are not a prediction
of future events or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of
the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such
forward-looking statements. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to forward-looking statements. We do not assume responsibility for
the accuracy and completeness of these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on
our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking
statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should carefully
consider the information contained under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF and all other information included
in or incorporated by reference in this Prospectus before making investment decisions with regard to our Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003" TITLE="enforce"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a corporation incorporated under
the <I>Business Corporations Act</I> (Alberta) (the&nbsp;&ldquo;<B>ABCA</B>&rdquo;). The majority of our officers and directors
and some of the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all,
or a substantial portion of their assets and a substantial portion of our assets, are located outside the United States. We have
appointed an agent for service of process in the United States, but it may be difficult for holders of Securities who reside in
the United States to effect service within the United States upon those directors, officers and experts who are not residents of
the United States. It may also be difficult for holders of Securities who reside in the United States to realize in the United
States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors,
officers and experts under the United States federal securities laws. We have been advised by our Canadian counsel, McCarthy T&eacute;trault
LLP, that a judgment of a United States court predicated solely upon civil liability under United States federal securities laws,
would probably be enforceable in Canada if, the United States court in which the judgment was obtained, has a basis for jurisdiction
in the matter that would be recognized by a Canadian court for the same purposes. We have also been advised by McCarthy T&eacute;trault
LLP, however, that there is substantial doubt whether an action could be brought in Canada in the first instance on the basis of
liability predicated solely upon United States federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We filed with the SEC, concurrently with
our registration statement on Form&nbsp;F-10, an appointment of agent for service of process on Form&nbsp;F-X. Under the Form&nbsp;F-X,
we appointed CT Corporation System as our agent for service of process in the United States in connection with any investigation
or administrative proceeding conducted by the SEC or similar authorities in United States, and any civil suit or action brought
against or involving us in a United States court arising out of or related to or concerning the offering of the Securities under
this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004" TITLE="thecorp"></A>THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the&nbsp;&ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we further amended
our Articles by removing the private company restrictions included therein and subdivided our 2,222,222 Common Shares issued and
outstanding into 6,750,000 Common Shares. On February&nbsp;9, 2007, we further amended our Articles to permit shareholder meetings
to be held at any place in Alberta or at any other location as determined by our board of directors (the&nbsp;&ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
3300, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two direct wholly-owned subsidiaries,
namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (Barbados) Inc., which is incorporated pursuant to the laws of Barbados; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Valens Pharma Ltd., which is incorporated pursuant to the laws of the Province of Alberta.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have two indirect wholly-owned
subsidiaries, namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (U.S.), Inc., which is incorporated pursuant to the laws of Delaware; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (U.K.) Ltd., which is incorporated pursuant to the laws of England and Wales.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Oncolytics Biotech (U.S.), Inc. and
Oncolytics Biotech (U.K.) Ltd. are wholly-owned direct subsidiaries of Oncolytics Biotech (Barbados) Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following schematic illustrates our
corporate structure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 347px; width: 551px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005" TITLE="ourbusiness"></A>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We focus on the discovery and development
of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional therapeutics. Recent
scientific advances in oncology, virology, and molecular biology have created opportunities for new approaches to the treatment
of cancer. The product we are presently developing may represent a novel treatment for Ras-mediated cancers. The product may prove
useful as an alternative to existing cytotoxic or cytostatic therapies, or as an adjuvant therapy to conventional chemotherapy,
radiation therapy, or surgical resections. It could also potentially be used to treat certain cellular proliferative disorders
for which no current therapy exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technologies are based primarily on
discoveries made in the Department of Microbiology and Infectious Diseases at the University of Calgary in the 1990s. Oncolytics
was formed in 1998 to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells
with an activated Ras pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lead product being developed by us
may represent a novel treatment for certain tumour types and some cellular proliferative disorders. This lead product is a virus
that is able to replicate specifically in, and hence kill, certain tumour cells both in tissue culture as well as in a number of
animal models without damaging normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, REOLYSIN&reg;,
is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an activated
Ras pathway. Activating mutations of Ras occur in approximately 30% of all human tumours directly, but considering its central
role in signal transduction, activation of the Ras pathway has been shown to play a role in approximately two-thirds of all tumours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functionality of the product is based
upon the finding that tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response
mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking
the activity of PKR are susceptible to reovirus infections. As normal cells do not possess Ras activations, these cells are able
to thwart reovirus infections by the activity of PKR. In a tumour cell with an activated Ras pathway, reovirus is able to freely
replicate and hence kill the host tumour cell. The result of this replication is progeny viruses that are then free to infect surrounding
cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour
cells carrying an activated Ras pathway available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following schematic illustrates the
molecular basis of how we believe the reovirus may kill certain cancer cells:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="paul" STYLE="height: 288px; width: 465px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For both non-cancer cells and cancer cells
with an activated Ras pathway, virus binding, entry, and production of viral genes all proceed normally. In the case of normal
cells however, the viral genes cause the activation of the anti-viral response that is mediated by the host cell&rsquo;s PKR, thus
blocking the replication of the reovirus. In cells with an activated Ras pathway, the activation of PKR is prevented or reversed
by an element of the Ras signal transduction pathway, thereby allowing the replication of the reovirus in these cancer cells. The
end result of this replication is the death of the cancer cell. The action of the Ras pathway in allowing reovirus replication
to ensue can be mimicked in non-cancerous cells by treating these cells with the chemical 2-aminopurine (2-AP) which prevents the
activation of PKR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006" TITLE="consol cap"></A>CONSOLIDATED CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise described below and
under the heading &ldquo;<I>Prior Sales</I>&rdquo;, there has been no material change in the share and loan capital of the Corporation
on a consolidated basis since March&nbsp;31, 2014, the date of the Corporation&rsquo;s most recently filed unaudited interim consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007" TITLE="proceeds"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated in an applicable
Prospectus Supplement relating to an offering of Securities, our present intention is to use the net proceeds we receive from the
sale of Securities to fund our core activities. Our key focus is on the progression of our clinical trial program which includes
the trials currently underway or which may commence during the period that this Prospectus is valid. The determination of the size
of such trials, their geographic locations, and the disease indications being tested are continually assessed and may change as
further information is received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding for our manufacturing program also
remains an important activity, as sufficient capacity to produce and provide GMP (good manufacturing practice) compliant product
is required if we are successful in our clinical program and our product is approved for commercial sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Continually developing our intellectual
property portfolio to expand and protect our core assets, our potential products, and the other necessary overhead costs for administrative,
marketing and general activities would generally conclude the allocation of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More specific allocations would be included
in an applicable Prospectus Supplement relating to a specific offering of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All expenses relating to the offering of
Securities and any compensation paid to underwriters, dealers or agents, as the case may be, will be paid out of the Corporation&rsquo;s
general fund, unless otherwise stated in the applicable Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008" TITLE="risk"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Securities involves
a high degree of risk. Prospective investors should note that there is no market through which the Subscription Receipts, Warrants
or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this
Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading
prices, the liquidity of the securities, and the extent of issuer regulation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should consider carefully
the risks incorporated by reference in this Prospectus (including in subsequently filed documents incorporated by reference) and
those described in any Prospectus Supplement before purchasing the Securities offered hereby. Discussions of certain risks affecting
the Corporation in connection with its business are provided under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF filed
with the various securities regulatory authorities, which is incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009" TITLE="desc of share"></A><B>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares. The following is a summary of the provisions attached to our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our Common Shares are entitled
to one vote per share at meetings of shareholders, to receive such dividends as declared by our Board and to receive our remaining
property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are
no pre-emptive, conversion or redemption rights attached to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at July<B>&nbsp;</B>24, 2014, we have
87,943,396 Common Shares issued and outstanding. After giving effect to the exercise of all our options, we would have 93,931,240
Common Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010" TITLE="prior sales"></A>PRIOR SALES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed under this heading,
no other Common Shares or securities exchangeable or convertible into Common Shares have been issued during the twelve month period
preceding the date of this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus, the Corporation issued an aggregate of 2,981,425 Common Shares, the particulars of which are set forth
in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 31%; padding-right: 5.4pt; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Date
of Issue</B>&nbsp;</P></td>
    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Number
of Common Shares Issued</B>&nbsp;</P></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Price
per Common Share</B>&nbsp;</P></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">December 4, 2013</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">35,000</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Cdn.$1.65</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">December 5, 2013</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">10,000</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Cdn.$1.65</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">February 27, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">292,793</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.5540</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">February 27, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">612,223</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.6640</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">March 11, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,884</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.6733</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 3, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,944</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.7267</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 7, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,944</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.7267</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 14, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,734</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.5399</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 17, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,760</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.5633</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 22, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,734</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.5400</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April 25, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,723</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.5300</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">May 1, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,633</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.4500</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 2, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 3, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,408</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2500</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 5, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 9, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 11, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 13, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 17, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 19, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,415</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2567</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 23, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,464</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.3000</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,430</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2700</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July 2, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,423</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2633</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July 3, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,423</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.2633</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July 22, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,588</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.4100</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July 24, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">101,565</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">US$1.3900</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus, the Corporation granted options exercisable for an aggregate of 1,716,000 Common Shares, the particulars
of which are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 0.5pt solid"><B>Date
of Grant</B>&nbsp;</P></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Number
of Options Granted</B>&nbsp;</P></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exercise
Price (Cdn.$)</B>&nbsp;</P></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">December 11, 2013</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,416,000</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.74</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">February 3, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.69</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June 18, 2014</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td>
    <td style="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011" TITLE="trading"></A>TRADING PRICE AND VOLUME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding Common Shares are listed
and posted for trading on the Toronto Stock Exchange under the trading symbol &ldquo;<B>ONC</B>&rdquo; and on NASDAQ under the
trading symbol &ldquo;<B>ONCY</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the market
price ranges and the aggregate volume of trading of the Common Shares on the Toronto Stock Exchange and NASDAQ for the periods
indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <td colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Toronto
        Stock Exchange</b></P></td>
    <td colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>NASDAQ
        Capital Market</b></P></td></tr>
<tr style="vertical-align: top">
    <td style="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>High</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Low</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Close</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Volume</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>High</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Low</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Close</b></P></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Volume</b></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Period</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(Cdn.$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(Cdn.$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(Cdn.$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(Shares)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(US$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(US$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(US$)</b></P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><b>(Shares)</b></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-decoration: underline"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>2013</u></b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.11</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.70</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.99</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,049,251</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.03</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.59</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.90</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3,087,206</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">August</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.04</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.75</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">912,029</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.95</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.59</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.65</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3,057,244</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">September</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.62</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.45</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.50</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3,864,673</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.50</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.38</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.44</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">14,156,295</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">October</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.49</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.31</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.78</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2,665,789</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.39</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.25</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.67</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">11,257,005</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">November</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.83</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.70</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.95</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5,936,921</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.72</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.64</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.85</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">16,759,137</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">December</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.99</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.54</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.66</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2,096,007</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.88</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.45</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.55</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">8,457,220</font></td></tr>
<TR>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-decoration: underline"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>2014</u></b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">January</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.10</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.65</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.75</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2,673,401</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.92</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.53</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.57</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">16,358,045</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">February</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.61</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.90</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">918,938</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.79</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.45</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.72</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5,967,943</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">March</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.31</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.78</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">907,737</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.07</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.61</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.81</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">12,113,726</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">April</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.20</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.54</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.68</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">893,221</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.40</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6,638,510</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">May</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.65</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.30</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.44</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,315,417</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.32</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4,907,935</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">June</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.52</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.34</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.37</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,380,819</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.39</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.24</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.28</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3,548,126</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">July 1 to 23</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.79</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.38</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.58</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">904,507</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.69</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.28</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.48</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5,827,509</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012" TITLE="desc of sub"></A>DESCRIPTION OF SUBSCRIPTION RECEIPTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a Prospectus
Supplement may be filed. The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and
the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement
filed in respect of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Receipts may be offered separately
or in combination with one or more other Securities. The Subscription Receipts will be issued under a subscription receipt agreement
(the&nbsp;&ldquo;<B>Subscription Agreement</B>&rdquo;). A copy of the Subscription Agreement will be filed by us with the applicable
securities commission or similar regulatory authorities after it has been entered into by us and will be available electronically
at www.sedar.com and, if applicable, we will file with the SEC as exhibits to the registration statement of which this Prospectus
is a part, or will incorporate by reference from a Report of Foreign Private Issuer on Form 6-K that we file with the SEC, any
Subscription Agreement describing the terms and conditions of such Subscription Receipts that we are offering before the issuance
of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Agreement,
original purchasers of Subscription Receipts will have a contractual right of rescission against Oncolytics, following the issuance
of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription
Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a Prospectus Supplement
and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission
is exercised within 180&nbsp;days from the closing date of the offering of Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Subscription Receipts described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Subscription Receipts offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Subscription Receipts
will be offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Subscription Receipts are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the procedures for the exchange of the
Subscription Receipts into Common Shares or other securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Common Shares or other securities
that may be obtained upon exercise of each Subscription Receipt;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of any other
Securities with which the Subscription Receipts will be offered, if any, and the number of Subscription Receipts that will be offered
with each Security;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms applicable to the gross proceeds
from the sale of the Subscription Receipts plus any interest earned thereon;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the material tax consequences of owning
such Subscription Receipts; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Subscription Receipts.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set forth in this
Prospectus. In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement
differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be
deemed to have been superseded by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013" TITLE="desc of warr"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may be filed.
The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Warrants.
Warrants may be offered separately or in combination with one or more other Securities. If applicable, we will file with the SEC
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a current report
on Form 6-K that we file with the SEC, any warrant indenture or form of warrant describing the terms and conditions of such Warrants
that we are offering before the issuance of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Warrants described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and aggregate number of
Warrants offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Warrants will be
offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Warrants are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of the Common
Shares that may be acquired upon exercise of the Warrants;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the date on which the right to exercise
the Warrants will commence and the date on which the right will expire;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Common Shares that may be
purchased upon exercise of each Warrant and the price at which and currency or currencies in which that amount of securities may
be purchased upon exercise of each Warrant;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of any Securities
with which the Warrants will be offered, if any, and the number of the Warrants that will be offered with each Security;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the date or dates, if any, on or after
which the Warrants and the related Securities will be transferable separately;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the minimum or maximum amount, if any,
of Warrants that may be exercised at any one time;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the Warrants will be subject to
redemption or call, and, if so, the terms of such redemption or call provisions; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Warrants.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Warrants described in a Prospectus Supplement differ from any of the
terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014" TITLE="desc of units"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue Units comprised of one or
more of the other Securities described in this Prospectus in any combination. Each Unit will be issued so that the holder of the
Unit is also the holder of each Security included in the Unit. Thus, the holder of a Unit will have the rights and obligations
of a holder of each included Security. The unit agreement, if any, under which a Unit is issued may provide that the Securities
comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. If applicable,
we will file with the SEC as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by
reference from a current report on Form 6-K that we file with the SEC, any unit agreement describing the terms and conditions of
such Units that we are offering before the issuance of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms and provisions of
Units offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply
thereto, will be described in the Prospectus Supplement filed in respect of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms of each issue of Units
will be described in the related Prospectus Supplement. This description will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and aggregate number of
Units offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Units will be offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Units are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms of the Units and of the Securities
comprising the Units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Securities that may be purchased
upon exercise of each Unit and the price at which and currency or currency unit in which that amount of Securities may be purchased
upon exercise of each Unit;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any provisions for the issuance, payment,
settlement, transfer or exchange of the Units or of the Securities comprising the Units; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Units.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Units described in a Prospectus Supplement differ from any of the terms
described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement with respect to such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015" TITLE="plan of distro"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell Securities to or through underwriters,
dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject
to obtaining any applicable exemptions from registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The distribution of Securities may be effected
from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at
the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers, including sales in transactions
that are deemed to be &ldquo;at-the-market distributions&rdquo; as defined in National Instrument 44 102 - <I>Shelf Distributions</I>,
including sales made directly on the TSX, NYSE MKT or other existing trading markets for the Securities, and as set forth in an
accompanying Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of Securities,
underwriters may receive compensation from us or from purchasers of Securities for whom they may act as agents in the form of discounts,
concessions or commissions. Underwriters, dealers, placement agents or other intermediaries that participate in the distribution
of Securities may be deemed to be underwriters and any discounts or commissions received by them from us and any profit on the
resale of Securities by them may be deemed to be underwriting discounts and commissions under applicable securities legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If so indicated in the applicable Prospectus
Supplement, we may authorize dealers or other persons acting as our agents to solicit offers by certain institutions to purchase
the Securities directly from us pursuant to contracts providing for payment and delivery on a future date. These contracts will
be subject only to the conditions set forth in the applicable Prospectus Supplement or supplements, which will also set forth the
commission payable for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Prospectus Supplement relating to any
offering of Securities will also set forth the terms of the offering of the Securities, including, to the extent applicable, the
initial offering price, the proceeds to us, the underwriting discounts or commissions, and any other discounts or concessions to
be allowed or re-allowed to dealers. Underwriters with respect to any offering of Securities sold to or through underwriters will
be named in the Prospectus Supplement relating to such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Warrants resident in the United
States who acquire Common Shares pursuant to the exercise of Warrants in accordance with their terms and under this Prospectus
and any applicable Prospectus Supplement may have a right of action against the Corporation for any misrepresentation in this Prospectus
or any applicable Prospectus Supplement. However, the existence and enforceability of such a right of action is not without doubt.
By contrast, holders of Warrants resident in Canada who may acquire Common Shares pursuant to the exercise of Warrants in accordance
with their terms and who will be deemed to acquire such Common Shares under applicable Canadian prospectus exemptions, will not
have any such right of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under agreements which may be entered into
by us, underwriters, dealers, placement agents and other intermediaries who participate in the distribution of Securities may be
entitled to indemnification by us against certain liabilities, including liabilities under applicable securities legislation. The
underwriters, dealers, placement agents and other intermediaries with whom we enter into agreements may be customers of, engage
in transactions with or perform services for us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offering of Subscription Receipts,
Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities exchange. Unless otherwise
specified in the applicable Prospectus Supplement, there is no market through which the Subscription Receipts, Warrants or Units
may be sold and purchasers may not be able to resell Subscription Receipts, Warrants or Units purchased under this Prospectus or
any Prospectus Supplement. This may affect the pricing of the Subscription Receipts, Warrants or Units in the secondary market,
the transparency and availability of trading prices, the liquidity of the securities, and the extent of issuer regulation. Certain
dealers may make a market in the Subscription Receipts, Warrants or Units, as applicable, but will not be obligated to do so and
may discontinue any market making at any time without notice. No assurance can be given that any dealer will make a market in the
Subscription Receipts, Warrants or Units or as to the liquidity of the trading market, if any, for the Subscription Receipts, Warrants
or Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable securities legislation,
and other than in relation to an &ldquo;at-the-market distribution&rdquo;, in connection with any offering of Securities under
this Prospectus, the underwriters, if any, may over-allot or effect transactions which stabilize or maintain the market price of
the Securities offered at a level above that which might otherwise prevail in the open market. These transactions, if commenced,
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016" TITLE="certain income"></A><B>CERTAIN INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable Prospectus Supplement may
describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities offered thereunder,
and may also include a discussion of certain United States federal income tax consequences to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017" TITLE="legal"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in the Prospectus
Supplement, certain legal matters relating to the offering of the Securities will be passed upon for us by McCarthy T&eacute;trault
LLP, with respect to matters of Canadian law, and Dorsey &amp; Whitney LLP, with respect to matters of U.S. law. In addition, certain
legal matters in connection with any offering of Securities will be passed upon for any underwriters, dealers or agents by counsel
to be designated at the time of the offering by such underwriters, dealers or agents with respect to matters of Canadian and United
States law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The partners and associates of McCarthy
T&eacute;trault LLP, as a group, beneficially own, directly or indirectly, less than 1% of the outstanding securities of any class
issued by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018" TITLE="auditor"></A>AUDITOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our auditors are Ernst &amp; Young LLP,
Chartered Accountants, Calgary, Alberta, Canada. Our consolidated financial statements as at December&nbsp;31, 2013 and 2012 incorporated
by reference into this Prospectus have been audited by Ernst &amp; Young LLP, independent registered chartered accountants, as
indicated in their report dated March&nbsp;12, 2014 and are incorporated herein in reliance upon the authority of said firm as
experts in accounting and auditing in giving said report. Ernst &amp; Young LLP has been our auditors since our inception in 1998.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ernst &amp; Young LLP has advised that
they are independent with respect to the Corporation within the meaning of the Rules of the Professional Conduct of the Institute
of Chartered Accountants of Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019" TITLE="registra"></A>REGISTRAR AND TRANSFER AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our registrar and transfer agent is Computershare
Trust Company of Canada at its principal office in Calgary, Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020" TITLE="docs"></A><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated by
reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada and filed with,
or furnished to, the SEC. </B>Copies of the documents incorporated herein by reference may be obtained on request without charge
from our Corporate Secretary at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7 telephone (403)&nbsp;670-7377,
and are available electronically at www.sedar.com. Disclosure documents filed with, or furnished to, the SEC are available through
the SEC&rsquo;s Electronic Document Gathering and Retrieval System (EDGAR) at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed the following documents with
the securities commissions or similar regulatory authorities in certain of the provinces of Canada and such documents are specifically
incorporated by reference in, and form an integral part of, this Prospectus, provided that such documents are not incorporated
by reference to the extent that their contents are modified or superseded by a statement contained in this Prospectus or in any
subsequently filed document that is also incorporated by reference in this Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our Annual Information Form, which is
comprised of our Annual Report on Form&nbsp;20-F dated March&nbsp;19, 2014, for the year ended December&nbsp;31, 2013 (the&nbsp;&ldquo;<B>AIF</B>&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management information circular dated
May&nbsp;9, 2014, relating to the annual general meeting of shareholders held on June&nbsp;18, 2014;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our audited consolidated financial statements,
together with the notes thereto, as at December&nbsp;31, 2013 and 2012, which comprise the consolidated statements of financial
position as at December&nbsp;31, 2013 and 2012, and the consolidated statements of loss and comprehensive loss, changes in equity,
and cash flows for the years ended December&nbsp;31, 2013 and 2012, together with the auditor&rsquo;s report thereon;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management&rsquo;s discussion and
analysis of financial condition and results of operations dated March&nbsp;12, 2014, for the year ended December&nbsp;31, 2013;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our unaudited interim condensed consolidated
financial statements, together with the notes thereto, as at and for the period ended March&nbsp;31, 2014; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management&rsquo;s discussion and
analysis of financial condition and results of operations dated May&nbsp;7, 2014, as at and for the period ended March&nbsp;31,
2014.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - Short Form Prospectus Distributions of the Canadian Securities Administrators to be incorporated by reference
in a short form prospectus, including any annual information form, comparative annual consolidated financial statements and the
auditors&rsquo; report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis
of financial condition and results of operations, material change report (except a confidential material change report), business
acquisition report and information circular, if filed by us with the securities commissions or similar authorities in the provinces
of Canada after the date of this Prospectus shall be deemed to be incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any similar document filed by the Corporation
with, or furnished by the Corporation to, the SEC pursuant to pursuant to section&nbsp;13(a), 13(c), 14 or 15(d) of the United
States Securities Exchange Act of 1934, as amended (the&nbsp;&ldquo;<B>Exchange Act</B>&rdquo;), after the date of this Prospectus
shall be deemed to be incorporated by reference in this Prospectus and filed as exhibits to the registration statement of which
this Prospectus forms a part (in the case of any Report on Form&nbsp;6-K, if and to the extent provided in such report).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
or in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for
purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed document
which also is, or is deemed to be, incorporated by reference into this Prospectus modifies or supersedes that statement. The modifying
or superseding statement need not state that it has modified or superseded a prior statement or include any other information set
forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an
admission for any purposes that the modified or superseded statement when made, constituted a misrepresentation, an untrue statement
of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement
not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute part of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a new annual information form and
related audited annual financial statements and management&rsquo;s discussion and analysis being filed by us with, and where required,
accepted by, the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta, Manitoba
and Ontario during the term of this Prospectus, the previous annual information form, the previous audited annual financial statements
and related management&rsquo;s discussion and analysis, all unaudited interim financial statements and related management&rsquo;s
discussion and analysis, material change reports and business acquisition reports filed prior to the commencement of our financial
year in which the new annual information form and related audited annual financial statements and management&rsquo;s discussion
and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales
of Securities under this Prospectus. Upon new interim financial statements and related management&rsquo;s discussion and analysis
being filed by us with the securities commission or similar regulatory authority in each of the provinces of British Columbia,
Alberta, Manitoba and Ontario during the term of this Prospectus, all interim financial statements and related management&rsquo;s
discussion and analysis filed prior to the new interim consolidated financial statements and related management&rsquo;s discussion
and analysis shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities
under this Prospectus. Upon a new information circular relating to an annual general meeting of holders of Common Shares being
filed by us with the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta,
Manitoba and Ontario during the term of this Prospectus, the information circular for the preceding annual general meeting of holders
of Common Shares shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities
under this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One or more Prospectus Supplements containing
the specific variable terms for an issue of the Securities and other information in relation to such Securities will be delivered
to purchasers of such Securities together with this Prospectus and will be deemed to be incorporated by reference into this Prospectus
as of the date of the Prospectus Supplement solely for the purposes of the offering of the Securities covered by any such Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_021" TITLE="where"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration
statement on Form&nbsp;F-10 relating to the Securities. This Prospectus, which constitutes a part of the registration statement,
does not contain all of the information contained in the registration statement, certain items of which are contained in the exhibits
to the registration statement as permitted by the rules and regulations of the SEC. Statements included or incorporated by reference
in this Prospectus about the contents of any contract, agreement or other documents referred to are not necessarily complete, and
in each instance you should refer to the exhibits for a more complete description of the matter involved. Each such statement is
qualified in its entirety by such reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual and quarterly financial
information and material change reports and other material with the SEC and with the securities commissions or similar regulatory
authorities in Canada. Under MJDS adopted by the United States and Canada, documents and other information that we file with the
SEC may be prepared in accordance with the disclosure requirements of Canada, which are different from those of the United States.
As a foreign private issuer, the Corporation is exempt from the rules under the Exchange Act prescribing the furnishing and content
of proxy statements, and the Corporation&rsquo;s officers, directors and principal shareholders are exempt from the reporting and
short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, the Corporation is not required
to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and copy any document that
we have filed with the SEC at the SEC&rsquo;s public reference rooms in Washington, D.C. You may also obtain copies of those documents
from the public reference room of the SEC at 100F Street, N.E., Washington, D.C. 20549 by paying a fee. You should call the SEC
at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference rooms. You may read and
download some of the documents we have filed with the SEC on EDGAR at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and download any public document
that we have filed with the securities commissions or similar regulatory authorities in Canada at www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_022" TITLE="docs filed"></A><B>DOCUMENTS FILED AS PART OF THE REGISTRATION
STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been filed
with the SEC as part of the registration statement of which this Prospectus is a part insofar as required by the SEC&rsquo;s Form&nbsp;F-10:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the documents listed under &ldquo;Documents
Incorporated by Reference&rdquo; in this Prospectus;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the consent of our auditors Ernst &amp;
Young LLP;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the consent of our Canadian counsel McCarthy
T&eacute;trault LLP;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">powers of attorney from our directors
and officers; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;F-X - Appointment of Agent for
Service of Proceeds and Undertaking.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED TO BE DELIVERED
TO OFFEREES OR PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the <I>Business Corporations Act</I>
(Alberta), Oncolytics Biotech Inc. (the &ldquo;Corporation&rdquo;) may indemnify a director or officer, a former director or officer,
or a person who acts or acted at the Corporation&rsquo;s request as a director or officer or a body corporate of which the Corporation
is or was a shareholder or creditor, and the director&rsquo;s or officer&rsquo;s heirs and legal representatives, against all costs,
charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual
in respect of any civil, criminal or administrative action or proceeding to which the individual is involved because of that association
with the Corporation or other entity, and the Corporation may advance moneys to such an individual for the costs, charges and expenses
of such a proceeding. The Corporation may not indemnify such an individual unless the individual acted honestly and in good faith
with a view to the best interests of the Corporation, or, as the case may be, to the best interests of the other entity for which
the individual acted as a director or officer or in a similar capacity at the Corporation&rsquo;s request, and, in the case of
a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds
for believing that the individual&rsquo;s conduct was lawful. In addition, the individual must repay any moneys advanced by the
Corporation if the individual has not fulfilled the conditions set out in the preceding sentence. Such indemnification or advance
of moneys may be made in connection with a derivative action only with court approval. Such an individual is entitled to indemnification
from the Corporation as a matter of right if the individual was not judged by the court or other competent authority to have committed
any fault or omitted to do anything that the individual ought to have done, and the individual fulfilled the conditions set forth
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with and subject to the <I>Business
Corporations Act</I> (Alberta), the by-laws of the Corporation provide that the Corporation shall indemnify a director or officer,
a former director or officer, or a person who acts or acted at the Corporation&rsquo;s request as a director or officer, or a body
corporate of which the Corporation is or was a shareholder or creditor, and the director&rsquo;s or officer&rsquo;s heirs and legal
representatives, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably
incurred by him in respect of any civil, criminal or administrative action or proceeding to which he is made a party by reason
of being or having been a director or officer of the Corporation or other entity if he acted honestly and in good faith with a
view to the best interests of the Corporation or, as the case may be, to the best interests of the other entity for which he acted
as a director or officer at the Corporation&rsquo;s request, and, in the case of a criminal or administrative action or proceeding
that is enforced by monetary penalty, he had reasonable grounds for believing that his conduct was lawful. The Corporation shall
also indemnify such person in such other circumstances as the <I>Business Corporations Act</I> (Alberta) permits or requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation maintains a directors&rsquo;
&amp; officers&rsquo; insurance policy for the benefit of the directors and officers of the Corporation and its subsidiaries against
liability incurred by them in their official capacities for which they become obligated to pay to the extent permitted by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the U.S. Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling the Corporation
pursuant to the foregoing provisions, the Corporation has been informed that, in the opinion of the U.S. Securities and Exchange
Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the Exhibit Index attached hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERTAKING AND CONSENT TO SERVICE OF
PROCESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1. Undertaking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant undertakes to make available,
in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when
requested to do so by the Commission staff, information relating to the securities registered pursuant to this Form F-10 or to
transactions in said securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2. Consent to Service of Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the filing of this Registration
Statement on Form F-10, the Registrant is filing with the Commission a written irrevocable consent and power of attorney on Form
F-X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any change to the name and address of the
agent for service of the Registrant will be communicated promptly to the Commission by amendment to Form F-X referencing the file
number of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
F-10 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of Calgary, Province of Alberta, Canada, on July 25, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="4" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>ONCOLYTICS BIOTECH INC.</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 50%"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 1%"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 3%"><font style="font-size: 10pt">&nbsp;By: </font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 1%"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 23%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Bradley G. Thompson</FONT></TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; width: 22%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Bradley G. Thompson</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person whose signature appears below
constitutes and appoints Bradley G. Thompson and Kirk J. Look, and each of them, either of whom may act without the joinder of
the other, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in
his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this
Registration Statement and registration statements filed pursuant to Rule 429 under the Securities Act, and to file the same, with
all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite
and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorneys-in-fact and agents, each acting alone, or their substitute or substitutes may lawfully do or cause to be
done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act, this Registration Statement has been signed by or on behalf of the following persons in the capacities indicated on July 25,
2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; width: 35%"><FONT STYLE="font-size: 10pt"><B><U>Signature</U></B></FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; width: 55%"><FONT STYLE="font-size: 10pt"><B><U>Title</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Bradley G. Thompson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Bradley G. Thompson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President, Chief Executive Officer and
        Chairman of the Board</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Kirk J. Look</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Kirk J. Look</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial and Accounting Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Wayne Pisano</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Wayne Pisano</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Ger van Amersfoort</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Ger van Amersfoort</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert B. Schultz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Lead Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Robert B. Schultz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Fred A. Stewart</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0pt 0">Director</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">Fred A. Stewart</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;/s/ Ed Levy</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"> Ed Levy</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ J. Mark Lievonen</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">J. Mark Lievonen</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ James Dinning</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">James Dinning</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Matthew C. Coffey</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Operating Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">Matthew C. Coffey</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Linda Hohol</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">Linda Hohol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Angela Holtham</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">Angela Holtham</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZED REPRESENTATIVE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section
6(a) of the Securities Act of 1933, the Authorized Representative has signed this Registration Statement, solely in his capacity
as the duly authorized representative of Oncolytics Biotech Inc. in the United States, executed in Alberta, Canada, on July 25,
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-left: 0; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Oncolytics Biotech
        (US) Inc.</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">By:</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD COLSPAN="3" STYLE="padding-right: 1.75pt; padding-left: 1.75pt; border-bottom: Black 1pt solid">/s/ Kirk J. Look</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 31%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 7%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 4%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 4%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 1%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Name: </font></td>
    <TD STYLE="width: 1%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="width: 52%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Kirk J. Look</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Title: </font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">Chief Financial Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="width: 1%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 90%; padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center"><font style="font-size: 10pt"><b>Exhibit</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Number</b></font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.1*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Information Form of the Registrant,
        which is comprised of the Registrant&rsquo;s annual report on Form 20-F, dated March&nbsp;19,&nbsp;2014, for the year ended December&nbsp;31,
        2013, incorporated by reference to the Registrant&rsquo;s annual report on Form 20-F, filed with the Commission on March 19, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.2*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management Information Circular, dated
        May 9, 2014, relating to the annual general meeting of the shareholders held on June 18, 2014, incorporated by reference to the
        Registrant&rsquo;s Report on Form 6-K, furnished to the Commission on July 25, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.3*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audited consolidated financial statements
        of the Registrant, together with the notes thereto, as at December&nbsp;31, 2013 and 2012 and the auditors&rsquo; report thereon
        addressed to the Registrant&rsquo;s shareholders, included as Item 18 to the Registrant&rsquo;s annual report on Form 20-F, filed
        with the Commission on March 19, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.4*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management&rsquo;s discussion and analysis
        of financial condition and results of operations of the Registrant, dated March&nbsp;12,&nbsp;2014, for the year ended December&nbsp;31,
        2013, incorporated by reference to Exhibit 15.1 to the Registrant&rsquo;s annual report on Form 20-F, filed with the Commission
        on March 19, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.5*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unaudited interim consolidated financial
        statements of the Registant, together with the notes thereto, as at and for the three months ended March&nbsp;31,&nbsp;2014, incorporated
        by reference to the Registrant&rsquo;s Report on Form 6-K, furnished to the Commission on May 9, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>4.6*</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management&rsquo;s discussion and analysis
        of financial condition and results of operations of the Registrant dated May 7,&nbsp;2014, for the three months ended March&nbsp;31,&nbsp;2014
        and 2013, incorporated by reference to the Registrant&rsquo;st Report on Form 6-K, furnished to the Commission on May 9, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>5.1</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consent of Ernst &amp; Young LLP dated
        July 25, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>5.2</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consent of McCarthy T&eacute;trault LLP
        dated July 25, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify"><font style="font-size: 10pt"><b>6.1</b></font></td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Powers of Attorney (included on the signature
        pages of this Registration Statement)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* - Previously filed or furnished to the
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MP``+"`!-`6,!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/9J*Y_Q/XWT7PC#NU.Z'G,,I;Q_-(_X=A[G`KS&\^,O
MB+7;IK;PMHNWG@^6T\GUP.!^1I@'Q@U`^8/M40/(!,$7Z<&D.H_%S1<R3075
MQ&O5?)BF!_[YR:OZ+\=9(;@6WB?2C"P.&EMP05^L;<_K^%>J:1K>GZ_8K>:5
M=QW,#?Q(>5/H1U!]C5^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO//B
M;\2E\*1?V;I1635Y5R2>1;J>A([L>P_$]L\UX-^$ESK<O]M^-)9V><^8+9F/
MF29[R-U'T'/TZ5Z]I^FV>E6JVVGVL-M`O1(D"C]*M45CZ_X4T?Q/;&'5K&*8
MXPLN,2)]&'(_E7C6N>%]?^$FK#6-"N7GTUF"LQ'&,_<E4<$>C?R->N>#/&%E
MXST5;VT_=S)A;B`G+1-_4'L>_P"==#111111111111111111111111111111
M111116)XO\1Q>%?#-WJDH#-&NV)#_'(>%'Y]?8&O+OA-X2D\1ZK/XNU[-P?.
M)@$G/F2YY<^R]![_`$KVRBBBBHKFVAO+:6WN8DEAE4HZ.,A@>H(KP6ZAN/@]
M\2HY8#(VD77."<[X2>5/JR'I^'K7OD4J3PI+$P>-U#*PZ$'D&GT444444444
M4444444444444444444444445XQ\==2EO-4T?0+8Y+?OF0?Q,QV)_)OSKUC0
M]*AT/1+/3;<`1VT2Q@CN0.3^)R?QJ_111117`_&70UU;P--=*H,^GN)T/?;T
M<?3!S_P$5-\(-8;5O`%JDC;I;)VMF/LN"O\`XZ0/PKN*:LB,<*ZD^@-.II=0
MVTLH;TSS3J*9)*D*[I75%]6.!3(KNWG.(9XI#Z(X/\JFHJ.6>*!=TTJ1CU=@
M*2&Z@N/]1-')C^XX/\JEHIH=2VT,N[TSS3J*8)49L*ZD^@-/I"P498@#U-(K
MJXRK!A['-(98P<%U!'8FCSH_^>B?]]"CSHO^>B?]]"GTTNBG#,H)[$TZBF23
M1PKNED1%]6(`ID-W;W!Q#/%(?]AP?Y5-15635+&%]DM[;(W3:TJ@_P`ZFBFB
MG3=#(DB^J,"*DKP_Q6/MG[06FPR\I'+;``^P#?SKW"BBBBBBLOQ/`MSX5U:%
MP"KV<JG/^X:\V_9_F+:5K,/.U)HV'XJ1_P"RUZVWW#]*^6?#>GZS-/?ZMH$S
MB\TK$Y1,EV0D@D>N.X[@FO>/A_\`$"T\::=M;;!J<*_OX,]?]M?5?Y?D3Y[X
MXR/CSI/)P9[0_P#CPKW*O-OBI\1KCPN8M)T<+_:5PF]I2-WDJ3@8'=C@]>GX
MT:/\)8+ZWCO/&5[>ZIJ$H#21O.P2,G^$8.3CZX]JT+GX.^$YB&M[6YLW'1[>
MY<'_`,>)KLK*SBT^RAM8-_E0J$7>Y=L#U)Y->;_%SX@WGALP:1HS^5>W$?F2
MS8R8T)(`7W)!Y[8]^+&B?"'3);.*Z\3S7>J:C*H>4RSL%4GL,')QZD_E5G4?
M@YX=FB9M*%SI=V!F.:"=SM/;()/'TQ7-?#OQYK%EXM?PGXDF-R1(\$<[G+I(
MN>"W\0..,\]*]CKPC02?^&B;@9./M=SW_P!AZ]WHKRKXC_#B<W+>)?"OF0ZC
M$WG30PG!<CG>G^UZCO\`7KI>!/BI8ZYH\PUN:.SU"RB,DY;A94'5U'KZKZ]/
M;D;R]UGXS^(OL6G^99>'K1\NY_\`0F]7/9>WYFO8=#T.Q\.Z5%I^FPB*",?4
ML>[,>Y-<]J7PJ\,ZKJ5Q?7=M<-/<2&20BX<`L>O&>*\C\0>%=-T_XN6F@6Z2
MKI\L]NC(9"3A]N[GKWKU/_A3?A'_`)]+G_P)?_&NX1%CC5$&%4``#L*\)^+;
M$?%;2\$C]U;_`/HQJ]XKS'XI?$:\T"[BT+00!J,R@R38!,8;A54'C<??IQZ\
M6-*^$5G<P)<^+;R\U;4'&Z3?<,$0^@P<GZY_`5=N/@]X4DD5[>VN;-U.=UO<
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MIZAJ=EI-J]SJ%U#;0H,EY'"C_P"O7A/@RSN/&/Q>FURS@=;"*[>Z>0C`4<[!
M_O'CCZU]`5X-HDB1_M#W#2.J*+NYR6.!]QZ]Q^W6O_/S!_W\%2QS1S*6BD1P
M#C*D&GU\]_&_2++3?%MO-9P+"UY!YLP7@,^XC=CU..:]Q\/:/9:%H=K9:=`L
M,"(#@=6)'+$]R?6M.BO"O%W_`"<%I_\`U\VG_LM>ZT5X-\7/^2KZ7_URM_\`
MT8U>\UX;\8=`OM+\7V_BB"%IK1C$SL!D1R)@`-Z`@#GZUZKX<\9:-XHLHY].
MO8C(PR\#L!)&?0KU_'I6K=:A:6,1EO+J"",=6ED"C\S4R.LD:O&P9&&593D$
M>HK,O=;T/[5)I=_?V'GE1OMIY4R0?536#>?"_P`&:DID&FPQ;N=]O*R#\@<?
MI7DOBVUB\`>)+>+P9K]S([\O#'+O,;9X5MO#9]",\>]?0>FRW$VEVDMXGEW+
MPHTR8QM<J-PQ]<UYO\=/#[7_`(>M=7@0F2P<K+C_`)YO@9_!@/S-=3\.?$R>
M*/!UI<,X-U`H@N1GD.HZ_B,'\:ZFBBBBBO(_CIXD"V5IX=M6W3W#":=5Y(4'
MY%_$\_\``1ZUWO@?03X:\'Z?IS@"9(]\W_71OF;\B<?A6\1D8-8'A_P-H7AB
M]FN](LV@GF38[&5WRN0<8)/<"N@KES\-_#']N+JZ::$O%F$X9)'50X.<[0<=
M>>E=12,JNA5P&5A@@C((KD]1^%WA+4Y3++I$<4A.2UN[1<_12!^E0VWPD\(V
M\@=M-:=AT\Z=V'Y9Q75V5C;:;9QVMC!';V\8PD<:[57Z"IG19$9'4,C#!5AD
M$>E<E?\`PK\)7\YF;2Q!(3DFWD:,?D#C]*AB^$?A-)A)+8S7##H)KF1A^6:Z
MVQT^TTRT2VL+:*V@3[L<2!5'X"K%<CJ/PM\*ZKJ-Q?7FGN]Q<.9)&%Q(,L>I
MP#BJW_"G?!O_`$#)/_`F7_XJNDT#P[IOAC3S9:1;^1`SF0KN+$L<#)))/8?E
M6G7/^(O`VA>*KJ*XUBS:>6%-B,)73"YSC@BMY%"(JJ,*HP!3J*P+SP1H5_XC
MBUVYLR^HQ,CK+YK@`IC:=H..,#M6_17/ZQX&T+7]8AU/4K-I;N$*J.)74`*2
M1P#CJ:Z"FR1I+&R2*KHPPRL,@CT(KD]0^%GA+493*^DI#(3G-N[1#\@<?I4=
MK\)O"-M(';3#.PZ>?.[C\LXKK+2TM["UCMK2%(8(AM2.-<*H]`*P=8^'WAG7
M;B2XU#2H7GD.7E0M&S'U)4C)^M8__"F?"8/%O=A?[HN6Q6WHG@/PYX=E6;3=
M+A2=>DSYD<?0L3C\*Z&H;NTAO[.:UNHUD@F0QR(W1E(P17@L<FH_!CQTZNLE
MQH]W_P"1HL\$=MZY_P`@U[II6JV>MZ=%?:=.D]M*,JZG]#Z$>E7****YOQKX
MUL/!FDM<7+"2[D!%O;`_-(W]%'<_UKS7X9^&+[Q?XFE\8^(,O$LIDAW#B64=
M"!_=7M[@#L:]NI"<*3Z5YM9_$'7KOPH-:33XW.'8Q)92^7M5B"?-WXQ@9)QQ
M7H&F7R:EI=M>1M&RSQ+)F-]R\CL>X]ZM5@:'K\^J>)-?TZ6*)(M,EB2-ESN<
M.FXY_P#K5OUSWBKQ)+H4FF6UK!&]SJ5R+>.29BL41]6(Y/L.,^M5/$7B#5O"
M=I;W]]]AO;5YTADCAC>*4%C@%,LP;Z<?6NLJ.<2F!Q`R++M.PNI90>V0",C\
M:Y2UUKQ!=>*[_1/-TM39P1S>;]GD.[?GC'F<8QZUUPSM&[!/?%!.`37"^%O%
MVM^)-/M;HPQ0"=V7Y=/E>,`,5_UF\#MUQQ7=U%<3"VMI9F5F6-"Y5!DG`S@#
MN:YKP]K6L^*='CU6S?3;6WGR8H71YG`!(^=@R@'CH!Q741[_`"U\PJ7P-Q48
M&>^*=7(Z#XVFU*&]-SI=X[6][-;JUK`70JC8'.>OK5[P1X@G\4>&(-3NH8X9
M9))%*1YP-KE1U^E=!1116#X+U^?Q+X<CU"ZBCBE:66,K'G&%<J.OTK>KD?$'
MBK5=,\6V^F:;IL5]%]B-Y,@<K,RA]I$?8GD'!ZX/-2:)XUBU_P`6-I]AY4ED
M-/%UOP1(DGF%"C`]"/0C-=56%XN\2?\`",:7#<+;^?+<7"6T89MD:,_1G;!V
MJ,=:M6D>M"6)KNYTYXC_`*Q(K=P>G\+%S^HK3I&944LY"J.I)P!0"",CD&EK
M*\1>'-/\4:4^GZI#YD3<JPX:-NS*>QKQ>ZT3QA\)-0DO-)D:[TEFRS*I:-A_
MTT3JI]Q^?:NQT'XXZ%?HJ:O%-IT_0M@R1G\1R/RKK;?QWX8N4W1:]IV/1IU4
M_D<&H;WXB^%+!"TVNV;8[0OYI_)<UPGB'XZ(^;7PO822S.=JSW"\9_V4')_'
M'TJEX8^%^L>*]4&M^-YIQ&Y#>3(V)9?0$?P+[=?8=:]HM[>&TMXX+>-(H8E"
MHB#`4#H`*EI*Q4\&^'XTV+I%H$_N;/E_[YZ5L11)#$L<2*D:#"JHP%'H!3ZK
MP:?:VMU<7,%O''/<D--(JX,A`P,GO@58J"\LK;4+9K>]MXKB%NL<J!E/X&J5
MOX:T>UN(YXM/@\V,YC=EW%#_`+.<X_"M2BJZ6%K%?2WJ6\:W4RA))0OS,HZ`
MGVJQ16(G@W0(EVQZ5;(N<[47:/R%;0&!@=!2UDR^%]%FG>9]-MO,D.7*IMWG
MU..OXUIQQI#$D<2A$0!54#``'04^J]G86NGQR)9P1P+)(TKA%P&=N2Q]S26.
MGVNF6JVUC;QV\"DD1QKM4$G)X^IJS1115>QL+73+46]C;QV\()81QK@`DY)Q
M]35BJ[:?:MJ"7[6\9NTC,2S%?F"$Y*Y],U'#I-A;ZE-J$-G!'>3KMEG5`'<>
MA/?H/RJY4<]O#=0/#<Q1S0N,-'(H96'H0>M9]KX:TBRG2:VL(8WC.4*CA/H.
M@_"M2JVH:?::K926E_;QW%O)C?'(N5.#D?J*FAACMX(X845(HU"(JC`4`8`%
M/HI",C!Z5RNM?#+POKKM)<:8D,S<F6V)B)/J0.#^(KG&^`OATL2M]JB@]!YD
M?'_CE/M_@3X:BE#2W.I3*/X&E0`_DH-=AH?@W0?#@!TK3((9,8\TC=)_WT<F
@MNBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"`%;`B<!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?Z****************************************
M************************************************************
M************************************************************
M*******************************************************BGN8+
M6(RW$T<,8.-\C!1^9JK_`&YI/_04LO\`P(3_`!H_MS2?^@I9?^!"?XT?VYI/
M_04LO_`A/\:/[<TG_H*67_@0G^-']N:3_P!!2R_\"$_QH_MS2?\`H*67_@0G
M^-']N:3_`-!2R_\``A/\:/[<TG_H*67_`($)_C1_;FD_]!2R_P#`A/\`&C^W
M-)_Z"EE_X$)_C1_;FD_]!2R_\"$_QH_MS2?^@I9?^!"?XT?VYI/_`$%++_P(
M3_&C^W-)_P"@I9?^!"?XT?VYI/\`T%++_P`"$_QH_MS2?^@I9?\`@0G^-']N
M:3_T%++_`,"$_P`:/[<TG_H*67_@0G^-']N:3_T%++_P(3_&C^W-)_Z"EE_X
M$)_C1_;FD_\`04LO_`A/\:MP3PW,2RP2I+&W1XV#`_B*DHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK#\1QI+<:(DB*Z'45RK#(/[J3M6G_9
MUC_SYV__`'Z7_"C^SK'_`)\[?_OTO^%']G6/_/G;_P#?I?\`"C^SK'_GSM_^
M_2_X4?V=8_\`/G;_`/?I?\*/[.L?^?.W_P"_2_X4?V=8_P#/G;_]^E_PH_LZ
MQ_Y\[?\`[]+_`(4?V=8_\^=O_P!^E_PH_LZQ_P"?.W_[]+_A1_9UC_SYV_\`
MWZ7_``H_LZQ_Y\[?_OTO^%']G6/_`#YV_P#WZ7_"C^SK'_GSM_\`OTO^%']G
M6/\`SYV__?I?\*/[.L?^?.W_`._2_P"%']G6/_/G;_\`?I?\*/[.L?\`GSM_
M^_2_X4?V=8_\^=O_`-^E_P`*/[.L?^?.W_[]+_A1_9UC_P`^=O\`]^E_PK-\
M+HL=A>(BA5&HW0"J,`?OFK;HHHHHHHHJGJY(T6_(."+>3!'^Z:Q='\*^'Y=$
ML)'T6P9VMHV9FMU))*CD\5=_X1+P[_T`]/\`_`=?\*/^$2\._P#0#T__`,!U
M_P`*/^$2\._]`/3_`/P'7_"C_A$O#O\`T`]/_P#`=?\`"C_A$O#O_0#T_P#\
M!U_PH_X1+P[_`-`/3_\`P'7_``H_X1+P[_T`]/\`_`=?\*/^$2\._P#0#T__
M`,!U_P`*/^$2\._]`/3_`/P'7_"C_A$O#O\`T`]/_P#`=?\`"C_A$O#O_0#T
M_P#\!U_PH_X1+P[_`-`/3_\`P'7_``H_X1+P[_T`]/\`_`=?\*/^$2\._P#0
M#T__`,!U_P`*/^$2\._]`/3_`/P'7_"C_A$O#O\`T`]/_P#`=?\`"C_A$O#O
M_0#T_P#\!U_PH_X1+P[_`-`/3_\`P'7_``H/A+P[@_\`$CT__P`!U_PIWA7_
M`)%'1O\`KRA_]`%:]%%%%%%%%%%%%%%8NO\`_'UH?_817_T5)6U7$>&[J]\:
MV&H:E-JEU9P?;)K>UALV5#$D;;=S$@[G)!//`!'%9^C>/+[3X9['6X7U"Y@U
MW^Q8[FV"H9F8!HV920`<'!QQQ6W'X]L3:W1GL[N"]M]173/L;!2\D[X*!2#M
M(((.21@9S5N3Q7%#>V^G36-U%J5S<-!!;NH`EVIYC.KYP4"]3Z\8S7(^+O%'
M]JZ=:163WFGW]GXAM+&[A,A1@&8'!*G#(PP0>]=,?&B;M6A_LNY^U:;=Q6KV
M^]-\IE(V,G.-IW#DXZ'TJMH_B_4M6F\01/HLD$6F74ULL\<\;<HBMR"<[CNR
M.,=B:-"\9V]]IFBP6BWNH7][8&\"S>6DGE*0I=\84$L0`!_($U:_X3BR;4XM
M.6UN4O)((I_LT^V&8K(2,*C$%BN#N`Z>]0_$C4;[2/"37^GW4MO<)=6Z!HP#
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M>!2NUS$J%.<9'WCG!YIL?Q$M&,+RZ9>Q6[ZJVD-/E&5+@-M'`;)4D8SBM.V\
M5PWMS,MG8W=S:P7OV"6YB4,%E'#';G.Q20"V..>P)KH*Q?#7_'G??]A&Z_\`
M1S5M4444444452UC_D"7_P#U[2?^@FFZ'_R`--_Z]8O_`$$5?HICS11LJO(B
MLQPH9@,_2A9HVD:,2(77EE#<CZBH9M1LK>\@LYKJ&.YN,^3"[@-)@9.T=\#T
MJSFBF2S1PKNED1%SC+,`*K3ZKI]M''+/?6T<<D@B1VE`#.>`H/J?2KE%&:*C
M:XA241M+&LC=%+`$_A4E%%%(?NFLGPK_`,BCH_\`UY0_^@"M>BBBBBBBBBBB
MBBBL77_^/K0_^PBO_HJ2MJL"T\+1:7>7T^DWMQ91WTK3SVZA7C\T]74,#M)[
M\X]JIR^`M.:STZV@GN(5LM1&IEP0SSW`).^1B.<DG.,=NF*9<_#^PO!J?GWM
MWOOKU+]9(RJ/;SH`JO&0.,!1P<]ZNW?A1+YK"XNM2O)=1L)O.MKS"*Z$KM8;
M0H4JPZC'-4[WP#87B,S7=RMQ)J,>IS3@*6EFCQL!R,!0`!@?_7I8-'74O'LF
MM/9W$$=G;BV$DGR+=R9)#[.X0%@&/4N<<`&K5IX2CL+O5YK74KN.+5)GN)H"
M$9!(R!6897/0#C.,BJ%C\/+/3(](:QU*^M[O2H&M8;I-A:2$G)CD!4JPSST!
MS5W5_!EEKD1AU&XGN82R/B4(S*RXY1MN8R<#.W'MBK?B?P['XGT@Z;/=36\)
MDCE+0A2V48.OW@1U45CZQ\/+'7?[0DOKZ[:ZOXXH9;A0@*Q1N)%1!C`&X`G@
MDU<G\&VTLVJ21WUU`-7C6/4$B*[9B%V%QD'8Q7@D>W<9I]MX0M+#71J>GW5S
M:*;6&T>UCV&)HXL[!RI(P"1P>E,TOP79Z5IUSI,=Y=RZ+,)%&GRE3'&KYW(K
M!=VWYC@$\4R+P6(O#5QX?.M:C+826SVD:R^66BB8;=H;:"<#@$YQ[U+9>$(+
M+6=,U)+VX:73]/\`[/C1E7:T60<GC.[Y1R/RJ?4/#::AXETS7&O)HY].25(8
MU52A$@`;=D9/W1CD8K*;X>VC6`M#J5WM&K_VP&VIGS]^_'W?NY[=?>M#3_"<
M.DZE>7-AJ-[;V][.;F>S4H8C*?O,N5W+N[@'%=".*Q?#7_'G??\`81NO_1S5
MM4444444452UC_D"7_\`U[2?^@FFZ'_R`--_Z]8O_015^BN<\:Z1-J6@FXL4
M4ZKITBWMBS#_`):ISM^C#*G_`'JHW.IO9^'6\1F&XM9]0EM\@6V^6*)BH56'
M\.`223G;D\'&*X_^VM7U&^\+W-]"TVKV5[J0\EH6B.1#((0W`^]\F#P#N'>M
M"3Q9K_\`P@LVKQZDIO1]E7R/L)$D,K.JS(P91G`+'`&1MSN(JU%XFU\VVIPI
M=Q7$EGJKPQS.@A,UOY088?:4#;B0"1AMI'!YJ?Q_</J/P@FGEMYEN)XK=_)E
MBQ('\Q"04&<'J2![UF^*]"-I&FJ?:(=VI:MIO[JUAQ%&L<N?,P<[FP<EC@84
M#M39O&6OKHMW!#///J<<^H0VKQ6(/G^3S$6X(&X=`%^;KD`&M&P\1:IJGB.*
M#^U_LUG_`&/!>/BV4`S;F$J`L,CA0<'D9KGH/&7BJ31UN'U0K</X?DU#9]A7
M(ND<`1=/XAGY>O'%;EQXSU1M;TY;=YOLOVNW2^!LSY<<4D.[(;!)^?`WY`R<
M8.":TO$?DGXF>$G;`\NWOM\FW.S*Q[<G&!R#C/H:YK3?&GBEK*TE$HOKNZL-
M1<6C6H39/"^(1Q@_..QZXXKO/"NHOJE@;K^TI+V-U3B2T\EXGV_.IX&>>V,C
MIS6_12'[IK)\*_\`(HZ/_P!>4/\`Z`*UZ**************Q=?\`^/K0_P#L
M(K_Z*DK2N;ZVM&C%Q,L7F9VE^!P,G)Z#CUH-_:`9-U!CC_EH._3OWIBZG8,"
M5O;8X7<<2J<#UZ].1^=(^JZ?&CN]];*J9W$RK\N.N>?>B35+*.2"/[1&SS2>
M4@5@Q+8)[?2I8;VVN"5BN(G8+N*JP)`]<>E4SK^FAH/])7;,%9'((4@[L<GI
M]QJL2:I81$+)>VZ,6V@&50<YQCKZ\5(;VU6,2&YA"$E0Q<8)'44UK^U6&*7[
M1&8YG$<;J<AF)P`"/>FG5+`?\OMOG=MP)03GTZ]>13#J]DH@,DIC$X)1G4JO
M`).6Z`X!ZGM4BZA;/=1VT<R/+)&9%"G/RC'/'U%0/KNG1OL>YP^2-NQLY'48
MQU]NM/M]8T^ZCDDANXFCC(#OG"@GW/%22ZA;11>87+INV9B4R?-TQ\N>]5UU
MW3V+J)7+("67RGR,8SQCMN7\Q4J:M92726JS?OWSMC*D'CKQCBHY];L+==SS
MY42&)F4$A6!`(/IC-3/JEA$NY[ZV5<;LF51QC.>OIS4\-Q#/N\F5)-O78P./
MKBLGPU_QYWW_`&$;K_T<U;5%%%%%%%%4M8_Y`E__`->TG_H)INA_\@#3?^O6
M+_T$5?HHHHQ11BBC%%%%%&*,4444A^Z:R?"O_(HZ/_UY0_\`H`K7HHHHHHHH
MHHHHHHK%U_\`X^]"_P"PBO\`Z*DJYJ.E6^J(B7!DVIG`1MO48JHGAC38X&A"
MRF-B209"<Y&&'T/<5'#X6LHYV=G=E7R_(`X,11`N0>Y(%*OA/2E^['*H"LJ@
M2D8W$DX_/^530>'-/MY8I(A*IB?>H\TX)R2,COC<W7UHA\.V4$DDD;SAY(S$
MQ\S^'C_XD4A\-Z>SEL2\DD+OX&2Q.!Z?._YTV'PQIENB)#'(BQ@!`'/R@.'&
M#UZ@?AQ0?#&F&R^R%)3"2Y8&0DMN(+9/U`/U%-N=(L+#1Y0WGM;VZR2[5DYS
MG<2/<$<5D26FD6"317#7$]Y""7VJ5RKN'P#TXR.<]_>M^70K::-8WEN#&L;1
M[?,XPQR3]?>F6?AZRT^59+9IT923CS20<XSP>.=JC\*;)X8TR=I6FC:5I059
MG;)P6W$9^OXCMBE?PSIDEK<6YB<17#AY`KD9QGCCMR?\@5/#HUG!&$17VB8S
MC+GAR",_K^?/6HT\/:<D@D$/S!(XP2?X4(('ORHSGKBGKHEDE\+T*YN`6(<M
MT)[CTXX_GFHF\.V+=3-C(8CS#@L%"[OK@#\JCC\*Z5#N\N)U#.[D!SC<ZD,?
MQR3]35VQTRWT^2XDA\PO.P:0NY8D_C6!HNH:A`M_'!HEQ<Q#4;K$J3Q*#^];
MLS`UM?VC??\`0$N_^_L/_P`71_:-]_T!+O\`[^P__%T?VC??]`2[_P"_L/\`
M\71_:-]_T!+O_O[#_P#%T?VC??\`0$N_^_L/_P`71_:-]_T!+O\`[^P__%T?
MVC??]`2[_P"_L/\`\71_:-]_T!+O_O[#_P#%T?VC??\`0$N_^_L/_P`75/5M
M0O3HU\#HMVH-O)DF6'CY3_MU?T3_`)`&G?\`7K%_Z"*OUSP\07,/EK/ITS%L
MYD12%7YR!D8)`P`<\]:?-X@GB?\`Y!<X0*S,[MM"X;;@\=><_3FE77KIHRQT
MBX1E9E96;^[U(..5(Y4]_05`GBF5B3_9-T00"@`.XCG/4#GC@=_:I[?7+AX#
M*UG+)OE8($4KA!MQU'7YCZ=#2MKUQ_9ZW"Z9<>;YNUX<9(08+-VSP>GK54^(
M-0M9I_/TZ6XB$Q1&B0J57>X#'/5<*N2.F1QS4ESXEN+5G,FE3[`K%-A+,Y#%
M<8"X'3/7H15B\UV6VFV1Z;<3+O*[EXX`SGIT/;U/I3KK69;:^FC-E,]O''N$
MJJ<,P(W#\`P/3L:IQ>+!+)Y8T^<."JLF<L"03R`.@QC/J<'!J7^WKJ6&^V6$
MD,L%N98UE#'S&!8;1@8(X'0_Q5#<Z]J<;7"+IK1X=U@9P3NVHK`G&0=Q+#J,
M8]>*NSZM,UA;SVZ+'.\BJT$J,WU7(^Z<<@GCIZU1_M[53D_V<=@\L@[&Y5A\
MYQV*'@COVJQ+K\]JD"2Z=/)/(A9A$IP,$@=1WQG&<\BMN*3S8DD"E0R@X88(
MSZTX_=-9/A7_`)%'1_\`KRA_]`%:]%%%%%%%%%%%%%%8NO\`_'UH?_817_T5
M)6U111111113)8DFB>*5`\;@JRL,@CTJI-HVFW$_GS64$DN`-[("<?6KJJ$4
M*HPH&`*6BBBBBBBBL7PU_P`>=]_V$;K_`-'-6U111111115+6/\`D"7_`/U[
M2?\`H)INA_\`(`TW_KUB_P#015^BFNB2*5=0RGJ",BG45GZB;OSX4B$PMV5O
M,>#;O#<;?O=OO9_"LW^TO$!F*_V4%A#$%N"Q7*C(^;&1ECCN!4<>H>(X[!!_
M9OF3J%!,A'S<?,>#V/;OD],5)%J/B&2'$FG)%(%)W@9!/'`7=QU/4\XICWOB
M0WIECT]?*7<HB8@"097!SGY3C?['&.^:='>Z^EQ(6L&:-YL#.,)'A0&`SGGD
ME<\<]<4L\VL);13PZ>$N5FD$D<87;(NUBI.3G!;'H:T-,NM1N&;[;:"W"@8_
MVCCKG)[YX[<=<UI48HHHI#]TUD^%?^11T?\`Z\H?_0!6O111111111111116
M+K__`!]:'_V$5_\`14E;517+NEK,\8S(J$J,9YQQQWK";7KZU4"XTV>68CE8
M8VVY"YR&P<@G&.XS@]*GM-<NKBZCMY=)GA9F(+DY0`#/!P,GVJO_`,)!>BY6
M4Z9/]D:`-@(V]'RV0>/8#'8^N:;)XM>"'S;C2YH58J$\QMN>,DG(XQS[?2I[
M?7+J\O+>-=/F@1B2_FHW*[6(YQ@$,H!SW/XTL&NW5Q8&?^S)D<1;V&UCM;Y<
MC&`3]XGCKM-,;6[^UN)8Y=-EN8ERR3PH1N7&?NX/.<C\,@=J2]UZ]@2.6+39
M6B4EI3CJ@5B<$@8Z`@]^G!I_]OW22NLFF3!5?:"H8C:0A#$[>!\QZ9QM-%WJ
MVH?8EFM["1)A<>4\;H7RNTG<,=<X`^O'6D_X2"[6&*0Z1<D%B'!4AEXR,#'.
M<@#WSG%13>(+]XDDM]+ERLB[T8-ED*DY!V_0?4$$=ZN7VL3V=W(/L;M:I"6\
MWH"^1\N>W!ZX[56EUK4G50FERPG?M+$%QP5R<`#@AC@^W08IDFLZJDMTG]GD
M+YLD<#[6/W58J3@<Y*@=NO4Y%6I=5O)-.AFM;,BY,A22WD!^7AL9..`2!SCH
M:RVUWQ`(P4TACN7*EDP<%L*2,G#=?E_'-=7$S-$C,,,5!(QC!I]8OAK_`(\[
M[_L(W7_HYJVJ********I:Q_R!+_`/Z]I/\`T$TW0_\`D`:;_P!>L7_H(J_1
M12;ER!D9-+2%U4@$@$\#)ZTM%(6`ZG%&]<@9&3TYZTI.*:'4G`89/;-.I"0!
MDG`I>M%%%(?NFLGPK_R*.C_]>4/_`*`*UZ**************Q=?_`./K0_\`
ML(K_`.BI*VJ****:\:28WHK8Z9&<4ZBBFNBR(5=0RGJ&&0:=1112.BNI5U#*
M>H(R*6BC%%%%8OAK_CSOO^PC=?\`HYJVJ********I:Q_P`@2_\`^O:3_P!!
M--T/_D`:;_UZQ?\`H(J_10:Y^XT"Z>2YFM;Q+>661W!"$X)P-P.<AL9!QP>/
M2H!H>NB21O[;8;\Y'S$?>S@`GY>.,CFIM4T+4+YB8M1V;9$DB+;LQE4(/0^O
M.>O)!XQ44ND:_&[SQZIYQ^<K$"RCD``#)QV/7U[4ZUT?5WTVYBN]1D$LJ!8O
MWC$QX.>2#WQZYY(R<"K+:+=312">_+2B59('*D^61D$X)_B4D$=*KS:%J;2N
M8-22.,.#`NP_NDP1M!SQD8&1Z9%2VVDZM#=B1]5+Q"?S-AW'*<_+R?3:/P)J
MNWAJZCNH;JVNHX9U>8NRA@&#ON`P#V&0<]>/04CZ!K30*O\`;<AD#`[PSKD?
M-Q@'U(Y]!4IT/4YK.ZANM22<31QHJNK%5*G)/)ZG^@J6PTO5K>Z$EQJ?G1@L
M1&=W!('?//?@\<C%;HHHI#T-9/A7_D4='_Z\H?\`T`5KT44444444444445B
MZ_\`\?6A_P#817_T5)6U111111111111111111116+X:_P"/.^_["-U_Z.:M
MJBBBBBBBBJ6L?\@2_P#^O:3_`-!--T/_`)`&F_\`7K%_Z`*OT44444444444
M444444C?=-9/A7_D4='_`.O*'_T`5KT444444444444452U+34U);?=/+"]O
M,)HWBQD,`5[@@C#'M47]F7?_`$&K[_OB'_XW1_9EW_T&K[_OB'_XW1_9EW_T
M&K[_`+XA_P#C=']F7?\`T&K[_OB'_P"-T?V9=_\`0:OO^^(?_C=']F7?_0:O
MO^^(?_C=']F7?_0:OO\`OB'_`.-T?V9=_P#0:OO^^(?_`(W1_9EW_P!!J^_[
MXA_^-T?V9=_]!J^_[XA_^-UG+%J!\226']M7GDK:+,/W<.=Q=EZ[.F`*T?[,
MN_\`H-7W_?$/_P`;H_LR[_Z#5]_WQ#_\;H_LR[_Z#5]_WQ#_`/&Z/[,N_P#H
M-7W_`'Q#_P#&Z/[,N_\`H-7W_?$/_P`;H_LR[_Z#5]_WQ#_\;H_LR[_Z#5]_
MWQ#_`/&Z/[,N_P#H-7W_`'Q#_P#&Z/[,N_\`H-7W_?$/_P`;H_LR[_Z#=]_W
MQ#_\;J;3=.33+9H4EDEWRO,[R$;F9V+'H`.I]*N444444445'<0)<VTL$F=D
MJ%&P<'!&#6+#X:EMX(X(O$&L+'&H1%WQ'``P!_JZ?_8%Q_T,6L?]]0__`!NC
M^P+C_H8M8_[ZA_\`C=']@7'_`$,6L?\`?4/_`,;H_L"X_P"ABUC_`+ZA_P#C
M=']@7'_0Q:Q_WU#_`/&Z/[`N/^ABUC_OJ'_XW1_8%Q_T,6L?]]0__&Z/[`N/
M^ABUC_OJ'_XW1_8%Q_T,6L?]]0__`!NC^P+C_H8M8_[ZA_\`C=']@7'_`$,6
ML?\`?4/_`,;H_L"X_P"ABUC_`+ZA_P#C=']@7'_0Q:Q_WU#_`/&Z/[`N/^AB
MUC_OJ'_XW1_8%Q_T,6L?]]0__&Z/[`N/^ABUC_OJ'_XW1_8%Q_T,6L?]]0__
M`!NC^P+C_H8M8_[ZA_\`C=']@7'_`$,6L?\`?4/_`,;K3L+*+3M.MK&`L8K>
M)8D+G)(48&3Z\58HHHHHHHHHHHHHHHHHHHHHHHHHK$3_`)'>;_L&I_Z->MNB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBL1/^1WF_[!J?\`HUZVZ***********************************
M********************************Q$_Y'>;_`+!J?^C7K;HHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK$3
M_D=YO^P:G_HUZVZ*********************************************
M**********************Q$_P"1WF_[!J?^C7K;HHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK$3_D=YO^P:G_
M`*->MNBBBBBBBBBBBBBBBBBBBH+Z<VMA<7`4,8HFD`/?`)Q6'93^*KRQM[H/
MHRB:-9`NR4XR,XZ^]3[?%?\`SUT;_OW+_P#%4;?%?_/71O\`OW+_`/%4;?%?
M_/71O^_<O_Q5&WQ7_P`]=&_[]R__`!5&WQ7_`,]=&_[]R_\`Q5&WQ7_SUT;_
M`+]R_P#Q5&WQ7_SUT;_OW+_\51M\5_\`/71O^_<O_P`51M\5_P#/71O^_<O_
M`,51M\5_\]=&_P"_<O\`\51M\5_\]=&_[]R__%4;?%?_`#UT;_OW+_\`%4;?
M%?\`SUT;_OW+_P#%4;?%?_/71O\`OW+_`/%4;?%?_/71O^_<O_Q5&WQ7_P`]
M=&_[]R__`!5&WQ7_`,]=&_[]R_\`Q53:+>W]S+J%OJ*VWGVDZQ;K<,%8&-'S
MAN<_-C\*UJ***************************Q$_Y'>;_L&I_P"C7K;HHHHH
MHHHHHHHHHHHHHHJEK'_($O\`_KVD_P#036'INM2.^FZ%8I&;I-+BNYI)<[(T
M/RJ,#DDD-W&`ON*9;>-H+6>_L]>06EW974-N[0*\L<GG#,3+@9&[I@C@CJ:O
MQ>,=#GMHIH;QI/-DEB6)87,NZ/\`U@*8W#;WR../44MUXOT*TA::6^'DHD<D
MLJHS)"LGW"Y`P@/OCUK(T[QBT7B#6[/5W1+:#4X=/L9(X6^9Y(U<*Q&<'+``
MG`Z5HP^---N/$*:+##?/.T<C^8+5]@V2>6P)QV;(SC''6F6?C'3G28W%RA=;
MFXA2*"&5G"PD!]R[<Y7(W$#'(P36E!K^FW5Z+2"X\V7Y02B,5!9-Z@MC`)0[
M@#VKF_%/C.]T#7+BQCBLC''I;Z@C3LREV5POE\="<\']*T[7Q;;&ZNHKYXK5
MH(K4M;G<TBR39VID#:^2,+L)R0?:FS^.M(BN[2UC6[GFN;F2T,<5LQ>&1(_,
M(=<;A\O(XY'/3FKC>+-#6^DLWU"-)8V=6W`A0R+O==W3*KR1GBL;Q+XS\CP^
M+W1)D,PN+5"+BW?!CFD"AP#@D$$D$9Z5T6F:WIVL6<US8W&^*&1X9=R,C1NO
MWE96`((]Q7,W7B^_3PE#XEM8;=K:\NH([:&4$$0R2B-7)'\1W!L=A@=>:Z::
MZNX]8LK4>1Y,T4CR$@[LKM''.,?-W]*Q9/%Q/BF70T:TM[F*>-!;W;F.2XC8
M*3+$>C`9(P,G*'.*OZ_JTVA265](R-IKSI;7*E>8S(P5)`?0,5!'H<]N9-(_
MY#.O_P#7W'_Z3Q5L4444444444444444444444444445B)_R.\W_`&#4_P#1
MKUMT44444444444444444452UC_D"7__`%[2?^@FL2R\/K<IH^M6EU)::A'I
M\=LSJH=98B`VUE/H>01@C)[&FWO@BWO(7)O9ENIK^&_N+DHI:1XBIC7'0*-H
M&!VSW)-5H?``MKL7UOK-W#?I>7%VDZ1H<>?CS$*D$%3M4CN"!S5N^\%6]]-J
MC&^N4AU>*.+48@%_?!%VY!Q\A*_*<=NF#S5'5?"12PUNWMUGNWUNXCD4*%C6
MS=554D#=<($1NY)7WK37PG'#K-AJEKJ%S!/:VIM)`%1A/&7#G=D'#%ADD>IK
M/MO``LK_`/M"UUJ[@OOM5Q/YR1I@K.P:2,J005W*I'<8ZFM)_"=O)XA@UE[B
M0W,+[PZJJNPVE=C.`"T?.=ISS^5-U/PJVHZ_)JRZE)`[V#6!C6)6'ELP8GG^
M+([\>QK,7X;6$;N8KZYC18[-;8`*3`UKGR6!/WC\S9SUSVJU/X&AEU"/55U*
MXBU47GVMKI40[F\GR=NP@C`3@=\\T^+P/:1RZQ']KG;3]6,K75H43#/(N'(?
M&\`]<9P">/2DF\&SW/AZWTBYUV[N([>>"6*62*/>!$P9%.`,\J,D\FKVA^'$
MT9-51KI[E=2NY+N4,@7:S@!@,=L**R[#PHTO@]?">I>:L-D8UM;R%@"R1N&B
M89SAUVJ"",$CN#6W_95TZR/-J<C7?D/##.L2J8=V,L%Y!.0#SQQTJA>^$DU-
MHTO]1N+FVCNX[Q8G5=RR(00%?&57<,X'J1G'%1:YHE]J]I::+--)/;-=K=7=
MW(JK^[27S%B4+CDD*N<<*"2<]='2/^0SK_\`U]Q_^D\5;%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%8B?\CO-_P!@U/\`T:];=%%%%%%%%%%%%%%%%%%%4M8_Y`E_
M_P!>TG_H)INA_P#(`TW_`*]8O_015^BBBBBD9=R%<D9&,@X->;^'/%.J6VD:
M1&T;:E=ZIJ5]:J]S<E-GE-+L_A/&V/'Z\UIZ5X^DUU-/CT[2RUY=::VHM!+.
M$`59/+V*V,%BV<$X&`,XS7:(^]0<$$C)!ZBG4444445CZ1_R&=?_`.ON/_TG
MBK8HHHHHHHHHHHHHHHHH)Q1D49'K1D>M&1ZT9'K1D>M&1ZT9'K1D>M&1ZUB(
M?^*WF_[!J?\`HUZV\CUHR/6C(]:,CUHR/6C(]:,CUHR/6C(]:3(]::\L<>-[
MJN>FXXIOVJW_`.>\7_?8H^U6_P#SWB_[[%'VJW_Y[Q?]]BC[5;_\]XO^^Q1]
MJM_^>\7_`'V*/M5O_P`]XO\`OL4?:K?_`)[Q?]]BC[5;_P#/>+_OL4?:K?\`
MY[Q?]]BJ>KW,!T6_`FCS]GD_C']TT[0_^0!IW_7K%_Z"*OT44444CJ'1E895
MA@UC1>$M!A6!8M,A06\C2P[<CRW;.YASP3DY/?)]:0>#_#P@M(!I%KY=FQ:W
M79_JLG)V^@/<=*T[:QM;-YWMX$B:XD\V4J,;WP!D^^`!^%6*******Q](_Y#
M.O\`_7W'_P"D\5;%%%%%%%%%%%%%%%%%%<CX:\.:)>Z!;7-UI-E//(79Y)(5
M9F.]N22.:U?^$2\._P#0#T[_`,!D_P`*/^$2\._]`/3O_`9/\*/^$2\._P#0
M#T[_`,!D_P`*/^$2\._]`/3O_`9/\*/^$2\._P#0#T[_`,!D_P`*/^$2\._]
M`/3O_`9/\*/^$2\._P#0#T[_`,!D_P`*/^$2\._]`/3O_`9/\*/^$2\._P#0
M#T[_`,!D_P`*/^$1\.9S_86FY]?LR?X4?\(EX=_Z`>G?^`R?X4?\(EX=_P"@
M'IW_`(#)_A1_PB7AW_H!Z=_X#)_A1_PB7AW_`*`>G?\`@,G^%'_")>'?^@'I
MW_@,G^%'_")>'?\`H!Z=_P"`R?X4?\(EX=_Z`>G?^`R?X4?\(EX=_P"@'IW_
M`(#)_A1_PB7AW_H!Z=_X#)_A6=K?A[1K"UM;FTTJS@G2^M-LD4*JPS.@."!Z
M&K-W:6UYXT@2ZMXIT73G(65`P!\Q>>:TO[#TG_H%V7_@.G^%']AZ3_T"[+_P
M'3_"C^P])_Z!=E_X#I_A1_8>D_\`0+LO_`=/\*/[#TG_`*!=E_X#I_A1_8>D
M_P#0+LO_``'3_"C^P])_Z!=E_P"`Z?X4?V'I/_0+LO\`P'3_``H_L/2?^@79
M?^`Z?X53U;1=*71KYETRR!%O(01;IQ\I]JETZY^R^'-+<QL^Z&"/`(XW!1GG
MZU)%KVFS#,=R&P0I`1L@GH,8ZGL._:HO^$FT@+O-X`G'SF-@O4#[V,=2!]2!
M3V\0Z8A8-<[2K!"#&PPQ.-O3KGC%,?Q'IX@9XY#(X3?Y00AL8!].,`@GTR,]
M:LKJ]HU\;,R8GWE`I4\D#/7ITJK'XDL'F=':2)1&LBN\;#>&)&!QUR.G4YXI
M\GB"SAO&MI"ZL`A4E#\^X@`J.I'S#)[=Z6/Q#IDLBHESN+$!2$;YB2RX'')!
M1L^F*<^MVQU&"QAS+-*S`XX"@!LG/<94CCN*J1^*;1[<O)#+%*8!<1PL`6D0
M@D$$$CL1ST-3CQ)I1=$-T!(YVJNULEL9P..O(_,>M/;Q#I:E@;H95BA^1N&X
MXZ=>1]<TZYUW3;-ML]R$/^XQ]/0=MPSZ9%-NM;@L[KR9D91A6$K$!&!SG!SU
M&,D=<'C/-`\0:89&C^T_.K;"NQLAO3&.O!_(^AJ)O$VFEML4CR%6PX6)\J,9
MSC'S#ITSU%6+/6].OY(DM+D3&52\;(I*LHQR&QC'(YS5?2/^0SK_`/U]Q_\`
MI/%6Q111111111111111116)X0_Y%>R_X'_Z&U;=%0W=S'9V<]U+GRH8VD?`
MR<`9/\JX^Z\2ZU#X$C\7HMH81;+?26)4Y,!`;:),_?"'.<8)XQWJ^_CS2(M3
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M1.IYV*6'G(!DD*<C`Y^85U#>-M*M[/[1*\\EO$\,5S=)"?+ADD52H;G*_?0G
MKC<,FHK'QU9SZ7>:A>6ES90VUZ]D/,VMYD@E\H*,'J6_`>M64\9Z9*T<<,5Y
M-.Z32&".W)D5(B`[8[C+``C.[/&:Q(?&;Z?XSUVVU.>X?2HI+&*V*VXQ`TZ_
MQL`"`6*@9SBN]HHK'\2_\@R#_K_M/_2B.F-_R.\7_8-?_P!&+6W111111115
M+6/^0)?_`/7M)_Z":ATJ"*X\.Z8DT:NHMX6`8="%!!J6/1=,A5UCL;=`XPVU
M`,CW_*HSH.G&Z6<VR85&41;1L^8@D[<=>!4O]D:=Q_H4!P0W*`\CH?K33HFE
MD`'3[<@8X\L=AC^7%2?V58?;/M?V2+[1NW^9M^;=C&<^N.*8=%TPL6-C!N(P
M3L'3.?YDU4U?[+`R&6TM)#*C`M.VT#:-PYP>,@?I6;#?Z.ES:H^EQ0.)%B.%
M4F)R$8<CMF4C/U[&K-Y=6MEJCE=/M&E3]Y'*)`&#L&R",<$@''7)/;-9UKJF
MFRW5E81Z(B13KE"5`"(P*E2,<,.A7I[UT\.DZ=`J"*QMT"-O7$8^4\'(]#\H
M_(>E-&BZ8-^+"W&_[V(P,\@_S`/X4Z?2M/NF9I[.&0MC<60'..E/;3[-\[[6
M)\@#YD!Z`@=?0$_G2?V;9;%7[+#A=N/D&1M)(Y]B2?Q/K42:)I<3%DL(%)ZD
M(/;_``'Y5+;Z;96DGF6]K%$^"H**!@$Y(^F1FJ.D?\AG7_\`K[C_`/2>*MBB
MBBBBBBBBBBBBBBBBL3PA_P`BO9?\#_\`0VK;HI&4.I5@"I&"#W%<_%X-TV+3
M!I7F73:4KAEL7ES$`#D)TW%,_P`))';IQ4-YX(TZ[U"[NY;N\66\N[>[<*Z`
M>9!CR\#;T&T<=\5)#X)TJ&RU#3]UU)IE]YGF6#S$PIYA)?8.JY))QG`)XQ45
M_P"!-,U.SN(+RXO9I)[>.U:X:4>:(D8.%!VX'S`$G&2>IJ6RT$R>*;S6[J`1
M.8%M8L29,RKG]ZX'`;YBHQR`3ZX$4/@73H-+T_34N[_[+IUS'<VJ-*K>6T9)
M11E>5&>_)[FK&G^$K+2[2>SLKN^BLY'+QVPG^2`EMQ"#&0,]B2.2,8.*MZ9H
M%EH]A<VEB#`ES*\TA0*/G8`$@`;1T'`&/QS6*GP]T4Z3#IK3WDT-K92V$!:5
M=T,4@PX&%QN*X&2"0.F*LIX&TE(IX2UR]O<F%KF!I!LG:(*%9ACKA5SC`.T9
MS0_@72I+&^LGEO#;7=T;SR_/QY,Q?S-\9`RIW\]3^7%33>$K6>ZL;UK_`%$:
MA:(T:WBS`221L061_EVE20#C'!&1BJ][X%TZ_NM0N);J]#W\MM+,%D7&Z`@Q
MXRO&,#/K73@8`R<TM%8_B7_D&0?]?]I_Z41TQO\`D=XO^P:__HQ:VZ******
M**I:Q_R!+_\`Z]I/_033=#_Y`&F_]>L7_H(J_111113'BCD&'16'^T,TAMX&
M!!AC((P?E'2@01`Y\I,\#[H[=*<(T!R%&>N<4ZBBBBBBL?2/^0SK_P#U]Q_^
MD\5;%%%%%%%%%%%%%%%%%%8GA#_D5[+_`('_`.AM6W1117&:;<-K-WXKN[LL
M&L;F2PMD#%?*C6)&+#'0LS$D^@4=JX[PYXDO-'3P_=W^H./[2T6'8MQ=/+'-
M-YB!I&'++)AP`!PY)RPQ706?CS5=3LM%:UMM/6XU#4+JP82.Q56B$A#?*<C/
ME].>O6LZ/6K_`,-:KXQU:"VM;B"+5;=+F`R,)&#11#$7;.78X/6K,_Q3>#[>
MZV]E<PPZ?'>0R0S$*2\_DX)(R47[Q?`X!XZ&H3KZ^'O%GBW5'-I<.+330/);
M;'F221"YY.`,@L?05LW/C/5;74M2TPZ;'<SV<L6)K4%P\4D;/D1YW,RE1E5)
M.&#>U/;5E'B/PKJ-@4,6O(\5RL>=L@6$R(^"`<J5*Y(!PV#T&$U2ZGMOB7MB
MF?8F@SW0A:1O+,BRH`Q4''0D?C60GQ0O[?3&O+W3;5O,T6#5H1#(V%$D@C*O
MD=%+;B1V!KO-.U!Y4VWEQ8,[R%8&MY<B9=N[H>AZ\`G@9SZ:5%%%8_B7_D&0
M?]?]I_Z41TQO^1WB_P"P:_\`Z,6MNBBBBBBBBJ6L?\@2_P#^O:3_`-!--T/_
M`)`&F_\`7K%_Z"*OT4444444444444445CZ1_P`AG7_^ON/_`-)XJV******
M************Q/"'_(K67_`__0VK;HHHK*.@VPU6YODP%O$"WENRAHYRHPK$
M'HP'&>XP#T&)DT/24MVMTTNR6!P`T8MTVD`Y`QC'!H?1-*DF$SZ;9M*'WAS`
MNX-C&[..N`!FICIUDUPMP;2`S*V\2&,;@W3.<=?>HDT;2XU54TVS55#!0L"@
M`-]X#COW]:=#I&FVT;1P:?:1(R>6RI"J@I_=(`Z>U']DZ=]F%M]@M?(#;A%Y
M*[0?7&.M0+HL)UI-3E;S)((C#:Q[0%@4XW8'J<#GT``[YGFTK3KFY-S-86TD
MY0H97B4L5/5<XSCVID.AZ3;,&@TNRB81F(%+=0=AZKP.GMTI\&E:=;)`D%A:
MQ)`Q:%8X541DC!*@#@D$CCUJY1116)XK$C:-&L+K'*;VT".R[@I\^/DC(S],
MBJMG%?1>-%%]=PW#'3FVF*W,6!YB]<LV:Z6BBBBBBBBJ]_`USIUU;H0'EA=%
M)Z9((K!L+_6+/3K6U;2[-FAB2,D:@,$@`?W?:K/]L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']L:M_T";3_P`&*_\`Q-']
ML:M_T";3_P`&*_\`Q-/T-+@7.I7-VD$4EU<+(L4<PDPHC1.3@=U-;5%%%%%%
M%%%%%%%%%%%8GA#_`)%>R_X'_P"AM6W61<>(K.RN98;LF+8S`,`6&`H.3@<?
M>Q0_B*P1PG[XN6*!5C).X8R/P!!_&HE\5Z6R.P:;,94,OE'(W+N7\QR*4>*M
M,,KQ[Y,IE6^3^+*C;]?F%.B\1VDWF2(28`4"R>NXL.G48VFH[KQ/;0VUI<QQ
MM)#/(R,S'88]N=Q(([8-(WBJR?;]F26<;E#E5Z`[NGJ?D/'I47_"::3)!%-;
M3^9&\B*Q((VJQ`#>_45?CU^PD:5`\@DB*JR,A!RS;0!Z_-QGI44?B.UNK:YE
ML4DG>!`VQALWY[`GO2?\)/IZQ&25V5`Q&54G:!N^]Q\OW6SZ;323>*M.AC#L
M+@J25&V$GH0#^1(ID/BNR>9HI1(CEW$6U"PD12`6!Q[@D=LU+/KX2WM[F&`-
M!-"TP:23RV4`9!*X)P?7U(XIL7B&-K^&TG@:&20F,_-N"R#!V\=B#U]J=>ZZ
MUE>R6[6I<!04=)1R=K,5(_A.%./7(Z4RR\0G4)X([>T.V7#9>3!"%0<XP>1G
M!!Q@X'.:W*Q_$O\`R#(/^O\`M/\`THCIC?\`([Q?]@U__1BUMT444444453U
M<XT6_(X/V>3_`-!-9VC:+I3Z%I[-IEFS&VC))@4DG:/:KW]AZ3_T"[+_`,!T
M_P`*/[#TG_H%V7_@.G^%']AZ3_T"[+_P'3_"C^P])_Z!=E_X#I_A1_8>D_\`
M0+LO_`=/\*/[#TG_`*!=E_X#I_A1_8>D_P#0+LO_``'3_"C^P])_Z!=E_P"`
MZ?X4?V'I/_0+LO\`P'3_``H_L/2?^@79?^`Z?X4?V'I/_0+LO_`=/\*/[#TG
M_H%V7_@.G^%']AZ3_P!`NR_\!T_PH_L/2?\`H%V7_@.G^%']AZ3_`-`NR_\`
M`=/\*/[#TG_H%V7_`(#I_A1_8>D_]`NR_P#`=/\`"LR]T^RL_$6A-:V=O`S3
M3`F*)5)'DMQP*Z*BBBBBBBBBBBBBBBBBL3PA_P`BO9?\#_\`0VK;J-K>%FW-
M%&3ZE133:P&,IY2!<8X4#`QBDBL[:"".&.%!'&H11C.`.@H-E:G.;:$YSG,8
MYSUIPMH%W8AC&XY.$')]:/LT&`/)CP#D#:.*1;6W1=JP1*O'`0`4@L[4$$6\
M((SC]V._6G^1#@CRDP>"-HYH\B'+'RDRW7Y1S]:7R8R2?+3)!!.T<YZTTVMN
M228(B6.22@Y/K0;6W.,P1G!R/D'7UH:UMW*EH(V*C:I*`X'H/:D:TMW+%H(B
M7^\2@R>W-+]F@W%O)CW'&3L&3CI3EBC4Y5%!YY`QUZT^L?Q+_P`@R#_K_M/_
M`$HCIC?\CO%_V#7_`/1BUMT444444452UC_D"7__`%[2?^@FJ6GZE:V6B:3%
M*Y,\MHACAC4N[@(,D*.<#(R?<5;TS6;'5TF-G/O:"0Q31LI1XGZ[64@%3]15
M_-&:RM,U^TU74M4L(%F6?395BN!(H`W,NX8YY&,?G6D9HUE6(R*)&!94)Y(&
M,D#\1^=1VMW'=B4QB3$4C1-OC9/F7@XR!D>XX-3YK$U+Q9I.D7LMG>2S)-%;
MF[D"V[N%A!PSD@'Y03SZ5H6FI6M](5MG:11$DHD"'8RN"5*MC#<#L>.,]:L-
M+&C(KNJLYP@)P6.,X'KP"?PI^:S-?UVU\.:1)J=ZDS6\;(K>2FY@68*.,CN0
M/QK3S6'=>*],LK.XOIGE%C#.+<W"1%U:0MMP,9)PV%STSQ6B^H1)<VUNR3>9
M<*63]TV!CKN/0?C59O$&GKJ]QI;22+=V]O\`:9%:-@HBR0&W$8QD$=>QI/[>
MMWT0ZO%!=26H7S"/)97V=V"M@D8Y]2.F:K7T\5UK'ARX@D62&625T=#D,IA8
M@@^A%;U%%%%%%%%%%%%%%%%%8GA#_D5[+_@?_H;5MT444444444444444445
MC^)?^09!_P!?]I_Z41TQO^1WB_[!K_\`HQ:VZ********I:Q_P`@2_\`^O:3
M_P!!-<O9Z9?V^LZ'X@MH#=VQT9;&>!7"O'DJX==Q`/0@C(/3KBLS6?"VKW]_
M?:K'9NLU[J-BWD),JLEO`WSLS!@-S`L,`GC:,U#:^'_$EHMO&UC/<Z5;ZI=N
M=.:\4,]M(/W)#%L'82WRD]P1T%6=4\-Z_<+JMO$MP_FV]NND7)O3NL'5<-O.
M=Q.[YB1NW#@U6U30KVTC\2ZI/']GNAJ<&H:=*TB@7+1QQIY9"DGYRK+M(_C!
MZU;;P=/#XJT357TA+M4@N/M6V8`PS22I(I&XC*KA@,?E5.W\/>(X+I&GTZ>Y
MTT:I?2R6(O%5FBEQY+CYL?(`PVY&-V1TK9M]$UJV\66UY$)6LPZI(MS-YFR(
M1;<I(&#$DXRC*P)RV15?Q1X=U#5?%D]VEE=R6;:++8A[>X6(M*TBL`<L,K@'
M.01[&L]?#WBZ.YNW$:C?'IGG)!,L<5QY.[[0B#/R!@1C@`A<'%-O?!FHS:Q:
M7S:6UUID&J23Q:=)<+OAA>WV-@EL`&7Y]H/`^N*NIX<\1MJ6MNTES%=S/<-I
MU^ETODQH\>V-'3[QV'M@C(W#FH;_`,.ZM?>`;BPBT6XM]2F^R++"]\LB.T<B
ML\@);`R%//#$XR.];WA72M2TZ/7[>:.:W@FO7ET\2S"39&R+T^8D?.&./>L&
MTT>\U;X/0:!:QHNKV`ACF@F;;^^AE5V!/;?LR&[A@:[!YK^>1;Q=+E1K>"1A
M!)+&&ED(&$!#$#IU)':N5USPUKFK^,I]3M%:R4:=`D+2LCPRS)([F.5`<LAW
M`9'0\]JZBUUJ\CL6NM;TLZ9'#;"6>1ITD17&=RKM.2.`0<#.<8S7.>%;&\TW
M1?!=K?1M%<*\[&)^L2LDC*A]U4JOX5WU%%%%%%%%%%%%%%%%%<MH&I'3-%@L
MKG3M3$T1<,%LW8??)X(&"*TO^$AA_P"@?JO_`(`R?X4?\)##_P!`_5?_``!D
M_P`*/^$AA_Z!^J_^`,G^%'_"0P_]`_5?_`&3_"C_`(2&'_H'ZK_X`R?X4?\`
M"0P_]`_5?_`&3_"C_A(8?^@?JO\`X`R?X4?\)##_`-`_5?\`P!D_PH_X2&'_
M`*!^J_\`@#)_A1_PD,/_`$#]5_\``&3_``H_X2&'_H'ZK_X`R?X4?\)##_T#
M]5_\`9/\*/\`A(8?^@?JO_@#)_A1_P`)##_T#]5_\`9/\*/^$AA_Z!^J_P#@
M#)_A1_PD,/\`T#]5_P#`&3_"C_A(8?\`H'ZK_P"`,G^%'_"0P_\`0/U7_P``
M9/\`"C_A(8?^@?JO_@#)_A5#5=2.IV]O;6^GZEYAO+9\O:.BA5F1F))&```3
M4\\\,'C:$S2QQ@Z<^"[`9_>+ZUK?VC9?\_EO_P!_5_QH_M&R_P"?RW_[^K_C
M1_:-E_S^6_\`W]7_`!H_M&R_Y_+?_OZO^-']HV7_`#^6_P#W]7_&C^T;+_G\
MM_\`OZO^-']HV7_/Y;_]_5_QH_M&R_Y_+?\`[^K_`(T?VC9?\_EO_P!_5_QJ
MGJ^H69T6^`N[<DV\G_+5?[I]ZFT/_D`:=_UZQ?\`H`J_1144MM!.T;30QR-$
MV^,NH)1O49Z'WJ6B@U@Z9KT]_P"*=;T=[:-$TP0GS1(29/-4L.,<8`]326/C
M+1KZQN+Q9I88(+AK9FGA9,R!]F%R/F);@`<^U1^&->N=:U'7H)O*\G3[Q;>$
MI$R,RF-7RP8]?GQVZ5T=%%,6&-96E6-1(P`9P.2!T!/?J:?13)(8YE"RQJZ@
MA@&&1D'(/U!K(U;_`)&#0/\`KO-_Z)>MJBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBH+BRM;HJ;BVAF*]#)&&Q^=0_V/IG_`$#K3_OPO^%']CZ9_P!`
MZT_[\+_A1_8^F?\`0.M/^_"_X4?V/IG_`$#K3_OPO^%']CZ9_P!`ZT_[\+_A
M1_8^F?\`0.M/^_"_X4?V/IG_`$#K3_OPO^%']CZ9_P!`ZT_[\+_A1_8^F?\`
M0.M/^_"_X53U;2=-71KYAI]H"+>0@B!?[I]JM:'_`,@#3O\`KUB_]!%7Z***
M***YR#PY?6>OZUJUIJD22ZH(@4DM=PB\M2JX^<9Z\YK-/@!_[-FLEUF4*NH_
MVG:/]G7=!/YADR>SC<3QQP?QK9T+P_)HU]JEW)?M<OJ,ZSR@Q!`'"*G&.V$%
M;E%%%%%%8NK?\C!H'_7>;_T2];5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%4M8_Y`E__`->TG_H)INA_\@#3?^O6+_T$5?HHID<L<H8Q
MNKA6*MM.<$=0?>GT49IB31N[HK@O&0'4'E21GG\*))8XMN]U7<VU=QQD^@]Z
M2*:*="\4BR*"1N4Y&0<$?@::UW;K,T+3Q"54\QD+@$+_`'B/3WIXEC+A`ZEB
MNX#/)'K41OK42-&;F$2(0&4N,J3TR.V:?%<P3EA%-'(5Y(5@<=1_0_D:EHHK
M%U;_`)&#0/\`KO-_Z)>MJBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBJ6L?\@2_P#^O:3_`-!--T/_`)`&F_\`7K%_Z"*OT45AW'ASSIVE
M2_N(6+.P\O`^\2<>XY'UP*9=>'6EMYA'>2F1D<1AF(4,0VW..>"W'H`!VI$\
M+H(PK7MQMWAR@<[1R"5'^R<=/4DTD?A8Q@@ZE<,68%R>K`$G;D<XY/'KCTJ:
M'P[Y=O+$U_.YD8%GP`QPFSG'?&#GU&:9_P`(S&=.:S>]N&!G6X60D%T=0,$$
M]\C=]:A;PLT2*+;4)TV*P15.T*6D+[N!U&>!WQSU-7-1\/PZG%)!--(EN]N8
M`L8PR@XS\W<'`R#UQ4:^'?*NUN8KR1725Y4RO=NH/J,U)>:"E]=2333_`'T,
M1"Q@'800RY]\D^QJQ8:6+"YFF$[2>:N""H&/G=_YR'\A6A116+JW_(P:!_UW
MF_\`1+UM44444444444444444444444444444444444444444444444452UC
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M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!`(((R#57^S;#_GRMO^_2_P"%
M']F6'_/E;?\`?I?\*/[,L/\`GRMO^_2_X4?V98?\^5M_WZ7_``H_LRP_Y\K;
M_OTO^%']F6'_`#Y6W_?I?\*/[,L/^?*V_P"_2_X4?V98?\^5M_WZ7_"C^S+#
M_GRMO^_2_P"%']F6'_/E;?\`?I?\*/[,L/\`GRMO^_2_X4?V98?\^5M_WZ7_
M``H_LRP_Y\K;_OTO^%']F6'_`#Y6W_?I?\*/[,L/^?*V_P"_2_X4?V98?\^5
MM_WZ7_"C^S+#_GRMO^_2_P"%']F6'_/E;?\`?I?\*?%96L#[X;:&-^FY(P#^
ME3T444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
%4445_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$@`=$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`*J:I?)I>DWNH2(SI:P/.R+U8*I;`_*K=8GC$3-X)U
MU8(VDF:PG5$52Q8E"``!U-`%2;Q1?Z?IXU+4]#:WL`%:66*Z20Q*<?,5P.!G
MG&3CL:Z"6[MX'1)KB*-W^ZKN`6^@/6N-U71GT^STZ_EDU#4M.A,8O-/FD:4;
M<C$H4<L48`E3D$9XR!6=J\,2:YXB&L2!$NMGV8/IIN3-#Y2C;&WJ'W_+V)SW
MH&>BSW,%L@>>:.)2<`R,%!/IS3MZE]FX;L9VYYQZUP<$%GIVMPMXB62XMQI%
MO!9SWL!?YEW><&`!`D;]V2.IZ#.#5-?M?AK0M%\0BQO'>W2XM7MBA>;[/(S-
M;JP'/RLL0QV#'T-`CT)KK%S%&BJZ/OW.)!\A7MCJ?PZ=ZDCN(921'-&Y!VD*
MP.#C./KBO/CHMQI-QX>M71Y9H])U%KF55)!GD\IG)/J6+'WIEK9VNBZ#X!OC
M:K96EML>\D,>WRRUHZAI,#@[B`2>YH`]&:6-%=F=55.6).`OU]*(Y$FC62)U
M=&&593D'Z&O-KTVFH0^(+J62XM;9M;MW2=K0R1MLAB`,B'&Z+(P3TZ'/&:W_
M``+<I-;ZE'!9V<<"7.];JPW"VNBR@LR*?NX/!`)&>^<T`=91110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%0W<TEO9SS10/<21QLZ0H0&D(&0H)XR>G-34CNL:,[L%11EF)P`/4T`
M5=+U&'5M*M=0@#".XC$@5OO+GJI]"#D$=B#4&O:S'H.CS:A)!+<%"JQP0C,D
MSL0JHH[DDBN-T2;6=;34[OPY<M965S>2M$T\8\I"#M+*C*68L07/*KEL#)S1
M->:MI'B+03XJNHYXU9HUDC0)"967:LH[AAR"K<`.2"<'`!Z$C%D5BI4D`E3U
M'M3J**`"CI110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`$<\;36\L:2O$SH5$B8W(2.HSD9'O
M7,ZAX:U63298!X@OKX^6H-O<I"J7`4@E&*("`V-I(/0UU54]1U6QTFW,]_=1
MV\05VW.<<*I=OR52?PH`POA_J5M?>%H(8I'^T6[.D\4J[)$;>W++VS@\].OI
M5'XBWUMY>CZ4$6YO[N_00V>`3(NU@V[^ZF"03Z$XYIMIX4@\3::^I7=S>V8O
MY&NH$LY!$\,;X(PX&X%@`S#.-S'BB;1[3P9>:?J\MU)-I\),-Q)<A"\1?"I,
MSA06(/R$MG`<GCF@9IQ>&-42RMH#XNU97BC1794@.\CJ>8R>?K735#:W=O>P
MF:VF66,.T>Y3D;E8JP_`@C\*YC5O$%]!XB-A:-E0-C1F'D9B9PX.<D9`&<;<
MY&<T".MHKSJ+Q#JMCI\[C4?M4Q$!B\ZW&UA]E5S@[AC<V3W/4`>FE<:]J-VL
MT,-Y;VUV9(5BMA`S2("T9+MSRI#'L/3.<T`=G17')KVN,9(P+0-;2".1F@?]
M[FX:($#=P-HW=3S[4+XFU--0CLWCMFD218SNQ']IS.\;,FY^-JH#@!N6`H`[
M&BN'M/%&KWL.FO(+>V^TM:3DK"V!%*[*8B6/W^!SQWXKN*`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**I7.L:99,
MRW6HVD#*,D23*I`_$U3'BK2)&"V\TUTS#(^RVTDHQQSE5([B@#9KE]0B_P"$
MC\2)912/%;:5E[B=%!+2R(5$0W`C`1BS<'J@]:EN?$=_)93-IN@7[3A6$37@
M2WCW8.-VY@V,XZ#O6+I6N2Z-IT-D!HZSEB]Q-=ZN@:25N6<A5.26SQV_"@#L
M+RX_LG1+BY^>?[);M)\QPS[%SR<=3CTK,@M[#QQX2TVYU6R#0W<$5T8/,;"L
MRA@,C!.,US>L^*+F_P##VK*E]IAA:SF&+>WGGR-A!&_"@<]\4F@7NM2Z+I<<
M<^L-&MG"W^C:9%$I`0?*&F//;D"@#H?#J_V-J%YX=DW>6C-=V4CL6,L4C%G!
M)Y+([$'V9#WKI*X272=9O[F"ZDL]5:2V#B$W.I0PGYN"?W*'&1[U/_PC6HS`
MM+9PLSH-WGZW=2X(''&T#\L4`=I5>:^M+<@374$1/3?(%S^=<E!X+N!ND>V\
M/QSR*=[&RDG^;U^:09_&K5OX.=`IDETI74%0;?2(TX/;DM0!M_V[H^2/[5L<
M@X(^T)Q^M5E\5>'9&;9K6GR-&>=DZL5_(\5!;>&9H(&C;6;@DG[T=K;)@>F!
M%5A-#G1B?[=U+!'0+`H_2,4`(?%6@F0Q?VI;,X_A5L_RILGB[0HD=FOAA.NV
M)V/X`#G\*/\`A'6(P^N:PWS;A_I"KCG)'"CCM].F*D/A^,DG^TM5R?\`I\>@
M"M_PFWA_R3+]N?:&V_\`'M+G/TVYQ[TZ+QGH$Q4)?-\Q(&Z"1>V>Z\4\>&8`
M0?[2U@X]=0E_QIS^&X'.?[1U9?\`=U"7_&@!_P#PDVC?\_\`'^1_PIK>*]"5
MU1M4MU9N@8XS^=-7PW"G34M7Z@\W\A_F:D_L%/\`H(ZG_P"!;4`#^)]#C0NV
MJV@4=?W@-1'QAX<55=]:LD5LX9Y0H_,U'-X7,LI==?UR($?<2Z&!^:DT]/#M
MQ&FP>(M8*XZ.T+_JT9-`%I?$6B,JLNL:>589!^TIR/SJS%J-C/((XKRWD<]%
M252?RS6+-X6GDW[=;N<D#:TEI;.0>_\`RRYS51O`ZE]_FZ;(Q'SM-I$#%SZD
MC%`'6@@C((/TI:XB3P+++%LFC\/38.5`TEH0/7[DO-,/A#5%FP$L/(!S^XO[
MRW+<>BN0/UH`[JBN*N=$U\J"GVA6)Y^S:[+D#'821D'GZ5`(/%4&R-6U]$4<
MNLUC<<=OOJK$_P"-`'>45P4.K^)8P"LMXV.-E_HC_-[[X6./^^:G'C6Z@@C^
MT)IOG/@#SGN+4$DX_P"6D)Q^)H`[:BN7M_&0F?:+&.;Y=W^B:C;R]\`8+J>:
MN+XGA"LT^EZO`%)R39/(,#OF/=D4`;E%8Z>*M#=PC:E#"Q&0)\Q9YQ_&!6C!
M>VMU_P`>]S#-QG]W(&X_"@">BBB@`HHHH`****`"N(U6?5KS5M5MK"2^EVN8
M#$%40+&;8,<-C._>P[YY';)KMZ0``D@`$G)]Z`.%O+GQ+_;5T+4W\=F8ID;,
M(D$3+M$;(-HSGYCP6..O(`IV_P`37%M'-#<7\(BCC`1H4+2L;@JS$E!QY?(!
M`(!!/-;OB'7+C1Q&+>TBN"8)[AS)-Y858E!('!R3G'M6++XYO$FEM5TA9+R'
M<[I'*SJ4$<<@`(3.XB4#D`#!.<4#(DO/$R:C;6[?V@1#>>66:%2DUO\`:&7<
M2$Z^7M))9>Q`.37=UR4WBW45>X>+2;=K>)9W#/>8<K#MWY4(<'YL`9ZCDBFP
M>*=1C9XI;2VF>>YGCLF%QLW!;@1@/\IVD!AZYP>A-`CKZ*Y%O&Q^WO:Q644^
MX`P2QW!V.?/2`@L4[,X/R[NF.M.7QE<--%"NC32RJ?\`21`YD"?OGB^4A<-S
M&S<[>/?B@#K****`"BBB@`HI"0H))``Y)-9=QXETBWD\K[8)YLX\JU1IW!]"
MJ`D?C0!JT5SMWXDN(8U<:<MI&W2;4[I+=?R&YOPP*H1ZMJ>H[?+N;N='!Q_9
MECY:?]_9S@_5<4`=@S!5+,0`!DD]JRIO$^BP2B$ZC#+*3@1P$ROGK]U,FL;_
M`(1VZO=K7&GVI;!&_4[E[QN?^F?"#\#6I!H$R0"*75)TC'2*SC2V0?3:-W_C
MU`$<GB64Q-);:+?L@`/FW02VC'/<R$,/^^:S3XJNIYA&E]H\!8$[+;S;^08]
MHPH!_.MN/PSHR/O>QCN)./WET3.W'NY)K42-(D5(T5$48"J,`"@#CXY=3O55
M&;Q#.QR2T<$5FF/^!X<=>QS1)X=OK[F;3;7/W<WVHSW7'.?DX7OTS7944`<U
M:^%Y[:5GCN[&U!`P+'38X\?BVXGO5X>'U=BUQJFJ3Y[&Z,8_*/;6O10!C1^$
M]!C96.F03.HP&N`9B.G=R?05I6]E:VBA;>VAA4=!'&%`_*IZJ:AJ=CI4`FO[
MN&VC)P&E<+D^@]3["@#D?BKK&JZ%X0GO;"WAN+1U>VO8Y,AE20;0ZD>C$<8Y
MSVQ3/A5K>K^(O"\=_?006UE&JVMG%&I+.(QM:0L>N3P`!QM/6M75-2M-?TF^
MTT:5JES:W,#1-(MIL4A@1E?,VY(ZYZ=*-(OK7P]H]CI8TC58+6U@$:R?9?,&
M%`&3Y9;KU_.@9I>)+^72_#]Y>P.J21*"':,N%RP!.T<G@]*Y9_$>O+=V\,;Q
M?9S(PANYXRHO/W@`7:JDC`)Z8SPW3-==;:AI6N0O';W$%TH(+QA@2I!XW+U'
M([UH4".(DUSQ!#%YTFT1W#$$FWV_8T$Y3?SG=\A!Y[C/3BBVU/7;B^M3]J`-
MQ%;HR)%O15,DVZ4'`^8JJ`]AGC(QGMZ*`//H/%6JW^I/#'))':^;;N)&M=I0
M-/L:-AD[?EQG)W#.>`0!/'XHU:**'<EN+HPAA8&)R[+Y.\RAB<[0WRX]L9R:
M[JB@#%\/7VI7:SQZFL0F18G_`'<90#>@8J<DYP<C.:VJ**`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@"K<:;879!N;*VF([R1*W\Q6>?"6@X7R],A@V
MD%3;9A(.<\%".];5%`&+-X<1O^/?5=6MCM`REXTG3/.)-P[UF7/@HS3>8;NS
MG."";S3(G;GT9-A__776T4`<4GA;5K2,K;FUY;/^CW]U;8&2>%W2+Z<8QUHV
M>*+)&`.J$*XQA[:Z4CC^\(WQU[YKM:*`.*'B;6;0_P"EK!M4C/VG3[BV&,#^
M-?,3UJW:>-4N'""R2=B2`+&^AG)QG^$LK=O[N:ZJJEWI>GWXQ>6%K<<Y_?0J
M_P#,4`9P\6Z6FT7GVNP+9Q]LM9(AP<?>(V_K6G::E8WX)L[VWN0.IAE5_P"1
MK-_X132XP?L@NK(G_GTNI(A_WR&V_I6;>>!X[AMZ7R2/M`+7ME#,21T)=51\
M_P#`J`.MHKBCX<UZP(-A=#8A^58+Z6/KU^242K^'%)_:OBC3SLG@FE"C):XL
M=X([X>W9N?K&*`.SDABE(,D2.0"!N4'@]1^-5[G2M/O`!=6-M,`P?$D2M\V,
M9Y'H,?3BN;@\=*',5S8H91T2VNT+-WX27RWZ>@-:8\6Z2A474D]D6.`;NVDB
M7IG[S#;^M`&O]EM]A3R(MK!@1L&"&^]^??UJ)-,L(YY)TLK=99"&=Q$,L0<@
MDXZYY^M.M+ZTOXO,L[J"XC_O0R!Q^8JQ0!2BT;3(9GFCT^U25VW,ZPJ"3N#9
MSC^\`?J,T2:1ITTT4LEC;M)"Q>-C&/E).XG\^?KSUJ[10`4444`%%%%`'-:Q
MX=EOK\2Q06URKG<[:C/++''R.%@!"G@>HYJ6'PU,T2QWFK7)C7_EA9*+2+'I
MA/F]OO=JZ"B@#.L=!TK36#VMA`D@_P"6I7=(?JYRQZ=S6C110`444@8-T(/.
M.*`%HHI,C)&1D=10`M%%%`!115'6-1&E:3<7GEF5XUQ'$O61R<*H^K$#\:`,
MW7O$(LFDL[66-)HT#W-RXWI:*QPI*CEW8\*@Y/\`/.TSP[>7<IOIY)[)I!_K
MI-LE[(/]IR"L0_V$`QZ@YIOAS2/M.I2W%W)]H2QF.YS]VXO2/WLI'HG$:#^'
M#>@KLZ`,8^%=%D)-Q9"[8D$M=R-,21T^^30WA30]Q:*P2V?<7WVK-"P8]P4(
M-3ZCJZZ?J6EV7V6>9[^5XP\8&V(*A8LWMQC\:TJ`./U;PS=QA;B&6;45AY3<
MX2\A'_3*?C/KM?(/0FK'A_Q').\-I?R";SBRVUZ(S&)67.Z.1#_JY5P<KT."
M1C!`ZBN/\4:3%!/]M$A@L[UTAO2G'E2D@0W*GLZ/M!/<$9^Z*`.PHK)\.:G-
MJFCI)=JJ7T+M;W:+T65#M;'L<;A[,*UJ`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`(KBUM[N
M/R[F"*9/[LB!A^1K)/A+1EW&VMGL6(QFQF>WQ^"$#]*VZ*`.0N_`L<DGFP7:
M-*.0UU;*S`]OWD?ER=?]HU`=*\3Z>C&VN+A\Y_X][P3#L?\`5W"DXZ\"2NVH
MH`XH^*=8TXL=1MX#&N?FG@EM?<?,!)'TS_$*WM$U]-:\P+:O$8QRXFBEC;_=
M9&/ZXK7JDVD::]Y'>&PMOM49W),(@'!P1][KT)H`NT444`%%%%`!1110`444
M4`9&NQZJ4@;2RQ=F,,BAE`17X\WGJ4(SCOS6'/:>)4ANY@]PTL+,;=(Y5P\?
MVDGD#AG\D`#/KZYK9US4[G3;JV>(!H5BEEG0CJJE,D=\A2Q`[UDOXQN([BS=
M[:$6ERGF(JDO,X9G\L;1RI954@D$9)!*XR0"!7\2-?VMQ)#?M&]Y(R09"!83
M*`N\@X!"`G#`Y!X(:M74;/5+K752-[F.PD>(2202*A"JDQ89^]RQC''X=ZRV
M\8W_`/9OGI'ISR&.*8LDI*QJZNVTC(+,-@SCG!SMXP73>.)(DFNUAM9+8"00
MPB0B9ML)E\P@CA#C'3."#WQ0!TVC+=KHUFM^7-VL2B4OC<6QR3CC/TJ]7'77
MBW4=-,[W=M9RQP&1&6W=R[,(/.&,C`&.#W[^U;>@:G=:G!<&[MUB>"7RP\9^
M67Y0<@'D=<<^F>AH`UJPO$9!GT:)R?*-]YC@=3Y<4DH'_?2+^5;M8/B<B"/3
M+Y]ODVU\GG;AP$D5HB3]/,SGVH`J:1IT^H?#RRAM-0GT^YN[=+D7<0#.LCGS
M"2&ZY).1W!-,G\9/I$<MMJVFW3ZA;JF\62;XYMY(0QDD<L5("'YL@]1R;OA:
MYCMO"EO%=.D)T\-:3%V`5#$=F<^F`"/8BN=\.21:Q\2]7U=9HKBR:(1V)1MP
M5XL)*WU.\`$=B?7D`BU'Q5-9:EIOB+7-'N;"PMDDB9'A=G@\W8/,9E!4XVX*
M^A)!.,'OX;ZUN+%;V&YB>U9-XF5QL*^N>F*=<PPW%K-#<*K02(4D5NA4C!!]
ML5YU\.M+T[7])GU.\M?M$?G"&..<-L8H@5I3&?EW,<DG'/ZT`>@V&H6>J6:7
M>GW4-U;.2%FA<.C8.#@C@\@U5\16RWGAK4[=UW![60`>^TX(]\X-7[>W@M($
M@MH8X84&%CC4*JCV`Z5F>*;K[)X7U&0`M(\#11*.K2/\B#\68"@#+\'71NKK
M49@3LNHK2\*D`8>2$!NGKL!^N:ZNN7\(VPANM6,97[/`\-C%M4@?N8E5NO\`
MM%A_P&NHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`(KFWCN[:2WF!,4BE6"L5)!ZC(YH^S0;XW\F/?$-L;;1E!TP#VJ6B@
M"`V-H8FB-K!Y;-O9/+&"WJ1ZTXVT!E:4P1F1DV,^P9*^A/I[5+10`TQ1G.47
MDY/'MC^7%,M[6WM(O*MH(H8\YV1H%&?H*EHH`*KWUE#J-A<65PNZ&>-HW`X.
M",<>AJQ10!YE':V5EXE^W^(+2*XN8(UM[YI"2BC.([P(?EVN`%<XRI'H":Z#
MQ/X5COFAUS2;IM.U:S`DCGA?:DR`<I(,$$%>,D''N!BMK6-'75(D>*;[->Q`
M^3<!`V`<91E/WD;`RO?V(!'#ZLFL:=H5]I"2PZ2MU"\*FY5I;)"XQF*4<Q#K
M\D@P,\<"@"W9V/BWQ7:VT]WJ<=CHL\".;=[=3/.",X?:V%!!&0"<XP1@D5I6
MTUYX/O(-/N8;G4-+O;@B&[AAW202R,21,JC&PD\.`,=".`:L:7XC$6FVT<FD
M:@$CB5!);(MS&0!CY6B+9Z>@ZCBI[CQ2L:$PZ1J4G&0TL(MT'&>6E*X_G[4`
M;]<'K>MS:K>0MIL(N(89MFG*Q^6]N^1O_P"N,(RQ;H2..@S'<ZAJ/B9FMD"7
MD+'!L["0BWQQ_K[H@;AR<I&,GH<@UT^BZ"-.<W=W(EQJ#QB(R(FR.&,=(HD_
M@0>G4XR2>,`%K1=+CT72+>PCD:4QJ2\K?>E<DL[GW9B3^-7Z**`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBH9;J&#=YTBQ*N,NYVKSGN?I3/[1LO-N(C=1![<J)@6`V%AE<_6@"S136D1"
M0SJ"%W$$]O7Z4&6,*S%U"K]XYX'?F@!U!`(((R#4,]W;VI032JAD8*@)Y8GL
M!1)=00VKW,L@CA1/,=G^7:N,Y.>E`&=<>%M"NMYDTNV5I/OM$GEL?Q7!K@/&
M.M^$?`=]96YT*.ZN&F#O'/"[MY14Y>)Y,J2#M!&>YKU8'-8GBGPKIOB[1WT_
M48SD9:&=.'A?&-RG^G0]#0`WP;K4OB+PCIVKRVR6S749<0IT1=Q"C\@*W:Q/
M!^BS>'/"6FZ/<2))+:1>4SQYVM@GD9]:VZ`*6L?:_P"Q+_\`L_/VW[/)Y&W&
M?,VG;C/'7'6N2NV\37XU"XMCJ-NB"XEL8MB(SL(H?*5@><;_`#>#C/.>,5W5
M%`'%22:YYLXD.K+.UP1/Y"*88[?S!M,1(R6V8Z9.=V1D"H(KKQ,;O3E\O4`B
MS(-[J,20&<C,@"8#B+:3DCV&<UWE%`'!:1:>(!+;V+3ZA#:$11R7+*OF@!+@
MO\S+_?\`+YQT(QP:=8ZMK3:UI,5[=7$<\\ZQ2VOE)Y9C^S;V+';E9-X)QGVQ
MCFN[J$6=L+LW?V:'[25V^=L&_'INZXH`FHHHH`****`"BBB@`HHHH`***,YH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@#"U#PVFHZU%?3M%)"C*QADBW`XCE3
MOQ_RUST[>]8LW@JZ:.$"2V<Q1PAEW%!,R0F,[CM;@=1P>I''6K6L3:\GB&5;
M`W;Q-;D11K$%C1MC_,6((;YMG!*D=L@FJ-W-JU[<6EW*=6M[:%Q\\%K^\R;<
MY^0J3C>0.G48X&30,O1^#3YUL\LL++%<P2,&!<O%'!Y?EECR1O\`FYS^=0#P
M5+;6]LEK]EVPI#YD'W5G=/,R6)5O^>@(R#]T=.*=<WGB;[-)`;61I!8_:BXA
M5D=S&%\C'][S-S?3`SS2:G=>((K%WADOOM4DETT02!=BA&(B3&QB<@`]MW/S
M#@4`,_X0R[7[+&#:RB%(@MQ-(S2P;(V0JAV\@DYSQU;CI5,^!=5=)DGDL)=V
MGO:;^09,P+&N_P"3)PRYR6(QC`!KJ_#XG\J_:>"6$M?3%%ESRN>&&>QZCZUK
MT".2T?PW>V7B:349VRC&5@RSC!#D;8R@0$A```2Q`QP!DXZF>>*VMY)YY%CA
MB4N[L<!5`R2?;%25%<RQ06LTMP0(41FDR,_*!D\=^*`.2D\2ZAXJTP_\(;&4
M)*AM0O$,<<9!!9`K*69L9'3`SU.,4^+Q?_PC]G;6OC#-I?[44W*+O@N3P&=6
M4?*!U(8#:#W'-3?#JYLKGP-IWV$C9$K1R*.JR!CN!';DYQZ$57\?:EI5C_82
M:EM?.I1R+&4\P[0&#-M[CY@.A^\*!G8@Y&1THH%%`@HHHH`****`"BBB@`HH
MHH`****`"BBB@`H``SCO110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!10**`"BBB@`HHHH`****`"BBB@`HHHH`YZ_\`
M$SV6L36OV1#;6Y@6>9YMA!E+!2JD88#`R<]SZ&JMAXOGO7>W73D%WYL2(OG,
M(RLB.X;<4!QA#T4@\8/IMG1+!]6?4Y8%ENF545Y`&\L`$?+G[OWCG'K4EKI6
MG6(_T6QMX<L&)CB`.0"`?R)'T-`'.:7XKOKN"V1[*.2_N8D9(EDV19+3?QD$
MCY8?0\X]ZG;Q1=0S7$7]GM<3!BZP1'+*BQQ%AD`AFW28'0'U%;9T;33#Y)L+
M?R\YVB,#G)/\V8_\"/K39M$TRXA6&2P@,:G(4(`!P%[=L`#'H!0!=C?S(U?:
MR[@#AA@CZBG4`8&!THH`*.M%%`'/:MX6BGMPVC2?V3>H$59K;**45L[&52`1
MC(&>F>*?I.DZ;IS16=S-%>:N\*332SMOFF*8'F88D@!L8QP":WJY7Q=C3+W1
M_$@P%L;D073$X_T>8A&)]E?RV_X":`.JHHSSCO7+^*[+5)KB&?2OM0G^S20A
MH9``FZ6$DX/`.Q7P>WY4`=117#WJ^)1<:B-.AO5`BFBB\R8."<H(V4L<=-YZ
M9S]XFI[F/7K*ZMA$^I74<=RX5`R8D0LF"[]1@;NHP1GD'%`'8T`@C(Y%<3`G
MB&=[1'DU2.5[M!J!/EB)4`D)\HXSM)"#Z8Z$FJME>ZW>:L]COO8IK;[-%)%%
M&@A56BWREB!@-SQ@]0N.,T`>@45P5O\`VU;:;;J3JD*&%1YD=L'F:58(PHD^
M4G!;S`3CJ`,@5H:5/XF;4K*34%DV2W$L5Q$(@(XHQ%N5@>I_>#&<\@X[9H`Z
MVBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`KDOB)IFOZIX4O(-`GB\YX7CEM98E83HPP0I/W7QG!Z<_0C
MK:J6NIVE[>7EI;R[YK-U2==I&TD;ASWX]*`//?@I+?7OAW5=1U.XN9K^;4&B
ME-Q]]?+1%"GZ>E>FUST?B#PQIUQ=+'>6T$LLQ><*"-T@`4D\=?E`_"I?^$R\
M/?\`05@_7_"@#<HJ.">*Y@CGA</%(H9&'0@]#4E`!2!5#,P4`MU('6EHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BL"Z\3"2
M[FL-#LWU6]A.V78^R"%O1Y2"`?\`94,WM3/[+\27R@WVO1V2M]Z'3+=<CCIY
MDFXGZA10!T5%<V_@RWF5?M&LZ],ZY^?^TI(\_@A4?I31X+CB(-IX@\06Y!R<
M:@TH)]Q*&H`Z:BN:-MXMTN/=!?6>M(#DQW<?V:4CV=`5)^JCZU<TOQ)::C=F
MPECFL=25=S65VNUR.Y4C*NONI(^E`&S1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`R9&E@DC61HV92H=<94D=
M1GN*Q-2BN]*T&.7^V;E19P?OYA:K-).0`-Q4#KQV]:WJIBXO?[3GA-E_H:0J
M\=P)1EY,G*;>V`!SGO0!SU]J?]E2VZ7_`(M,#31^8BO9J"R^O3C\:FT_Q!IZ
M.)9_%$%U&PVA&1(^>#G@`]*G'B'4\?\`(I:O_P!_;;_X[1_PD.I_]"EJW_?V
MV_\`CM`&A!KNE7,Z0P:A;22N<*BR`DGVK0JK87<MY;^9-8W%FX.#'/L)Z?[+
M$?K5J@`HHHH`****`"BBB@`HHHH`9)+'"F^6144=V.!3MR[PFX;B,@9YQ7,>
M*["]OW>&TA$CS:=<PQ%\[%E;9U/8E0P!^OK67<:)K[W0GMDG@LU#`0-=;[@1
MF2$N@DW'!8)(1\W&<9&>`#O*0$,`000>017'0V&L!D\^#49(B"+9!>@>2#(Q
M_??-\WR;!SOZ$=>3G6^D^)M.\*V5C)]KFNK41A5M951'40[1&<.K*%88R"<G
M#$$$@`'H=%<MXEM-7N/LMQIT=PMX+2:/$,X"H[F/KG@X`?!QU';-9UU;>*'U
MFYBL_MT5H(Y8@[3*V?E01NI8]<[C]W(YR30!W5`((R#D5QLL'B*SO(5C-]<P
MI=OY:&1</$6C(+OG((^?&001D<'!J""S\0VU]I\$4%S'`A`F"R*8RC%RW<8(
MROJ>F,4`=P""2`1D=?:EKSNPL/$UGI%G;SC4%MULXH\6K1FX2=85&68GYEW;
MNYZ#M6WI$/B-=82?4WE,;O*DB*Z^4$"IL(7J"6WG/USVH`ZFBBB@`KE+^XO/
M$VLS:+I\S6^E6AV:G=QDAY'(SY$;#H<$%V'(R`.22-K7]2.C>'M1U(*&:VMW
ME53_`!,%.!^)P*C\-Z6='\/6=G(2UPL>^X<G)DF;YI&)]2Q)H`O65E:Z=:1V
MEE;QV]O$,)'&H55'TK*UO4[^VU72-.L!;J]_)*KRSJS"-40MD*",G.!U%;E5
MYK&VN+NVNI8@T]L6,+Y/R;A@_F*`.4OO%M[8W2R;K6XM3J,=F5M[:9@J.XCW
M&;A-P8\KCC&,YJSI_B+4)-?2RU%;:R$DTT:6\L,BNX7.QHY?N2949(&"!GT-
M7Y/".BRRJ[VTA5;@721?:)!&DN_?O5-VT'<,\#N?4U-!X;TRWO$N8X9-T<KS
M1QM,[1QR-G<RH3M4G<W0?Q'U-`&K6?J^BV6MVJPWD;;HVWPS1L4EA?LR..5/
MT^AR*T**`.=T'4[V"_E\/ZT^_4($\V"ZP`+V#.-^!T=<@./4@CAACHJY;QUF
MRT>'7X5)N='G2Y&/XHB=LJGV*,WX@'M74`AE#*001D$=Z`%HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*KWE]!8K$TY*I)*L08+D
M!FZ9]!GC/N*L57O[&VU.QELKR(2V\R[70DC(^HY%`&9;^*+"ZDC2`3S>:N]!
M'"Q(7RUDRW'HZX]<@=:99>)K6]U*WL+6%ADR)*&(!A9$1PN!D'(D'0\=.M76
MT+3FEGD^SX:=&CDVL0"I14(`!X^5%''I45AX;TS3;K[3;Q.)M[/O:0GDHJ'C
MI]U%'X4`56\9:6EV]NZ7:E"^7,!V[5D\IFSZ!R![]1D5EZ=XWGOKPQ?98#S<
M;X49_,B2(N-[$KM*DH!P>"PZUOR^&]*F9F>V)9D="=[9VM()".O]\9IQ\/:8
M888A;E4A:5DVNP(\W=O&<YP=Q..G3T%`&3!XSB:S2XNK1K<I8RW-S$7!:&1#
M&/+]#GS`0>XP>]:^A:L-9TM+HQK%,KO%/$L@<1R(Q5E##J`0>>XJ-_#.D270
MN6M`9?*CA)W'#)&P9`PS@X('7Z5=M;"VLI+A[>(1^>XDD"]"P4+D#H.`.E`$
MEQ*\-O))'`\[J,B*,J&8^@W$#\S6!_PF=I;$'5M.U/28R<>?>0#R1_O2(651
M[L1724UT62-D=0R,"&5AD$'L10`JL&4,I!!&01WI:Y3PJ'T?6=7\,LQ-M:E+
MO3PQY6WES\@]D=6`]BH[5U=`!1110!SUWJ%ROB2.VM;X2B,[[FV"+B.+8<#^
M\9&8`@#MG([FK>>([A-<@DB69-+@,<5UO@P-\O3<QY0IF,D?]-.>E=.;>`S"
M8PQF4='*C<.W6LGP_>SZI;ZF;V*';'J%Q;QA5&&C1MH+#)YXH`I:-<:Q=ZCY
MWF3O9_:;A)C,(O+VJ[J@BV_-D$`'=V![XKIZ1551A0`,YP!2T`%<K#K>J/?-
M&D4*V\,T2N)$=G<27$D9PV>,!5;H>O88KJJP)/%=BI08E5M^V16CR4.74J<'
M@YC?UZ>]`&%_PE=_9LKW!B\F1$=05<_9Q]E,GS\Y;+C'.*8?%FISRVA\VW5,
MWB2K&!B0QB,H00S8/S'@,:V9/&-I%/:03V,]O->(/+65HL@G=L#`.3R`3P"!
MGFK,VO06FDZ?<36$TTLUOYZP6L8<HJH"Q&<<#<!ZG(P*!F5'XNO[BY6&"&SD
M>=]J@,Q-J?.$9$W/)()(`QDJ1[UI-KTZZ'8W+_9H9[F<V[2R$^3&PW#<>^"4
MP!D<L!FH%\9Z$L\RHLF\1&9BD8)<A`^W`.[=M/<8[9SQ3KKQAHUO"([R*6,D
MOYD$L:Y148*S,,X(R1TR>>G6@0WPSK=WKFIWDLV8H(K>$)``<;F+[FR1R#M!
M4@_=(XR:Z>L)_$UJL-Q)!!(T5I<+!.Q&T(-^PL.O0\X...>F*W:`"BBB@`HH
MHH`Y_P`=6\EUX%UJ.%&DD%J[JBG!8J-V/TJU>3W&I^'XKG2G;-PD<JE&"NT9
M()"D\!BN<$]_SK6(!!!&0:Y70KD>'=0'A>]^2$EFTF8C"RQ=?)S_`'TZ8[J`
M1T.`"U86FNQV-_)<73F[:(I9H[JRI\N5+8&"V3@GH<5FP:?XFBNW,<URD$L^
M]?-FC=TY0,7[%=H;:J]#UZ\=E7"W:^.)99'AQOBNV9(P46(IME"\YRRX,1(/
M\7I0!>AM_%\\SQW5S%#!YB$/!MW%,A7'(.#A2^?67'\-0/;^*FNTCD>X>$1P
M[VCDC3!612V"/O%E#`YQU[YXF@_X2J:V@9[AT_>("1"@;:9<,6#=PG.0!VX/
M0Q+<^,#+)OC"$6XVJ(E96.P9;/9]Y/RY(P.G>@!(X?&$5S:.TKR+Y1DE0F,Y
MD)<LA/``QY84@''/7FDT^#Q?=#9=SS6T2R*8W!B+NA90P?@\A?,QC';TK7T5
M=774[L:E+,\(39"650K8ED^8[?XBOEYZ?2MV@#C_`!9)=V_POU"'4"9+V:T-
MH2N,O)(?+7IQDEATKK+>+R+:*+.=B!<^N!BN9:<>*/$T,4`WZ/I$GFRSC[L]
MT.%13W$>23VW;1U4UU5`!1110`4444`%%%%`!1110`4444`4M6O7T_3);B)`
M\@*JBMTW,P49]LD5BZGXHEMO[0CA@C_T>.1DGWEE+(4!!&`!][LQ/'.*Z&[M
M8KVUDMIU)CD&#@X(]"#V(/-9EY_8=C<RR7=O:+(R`N[1JSMO;&,`9.2/Q(H`
MI0^*)V+@V2RB&0)*ZRA""\C(@53][H,\CKQGI3(?&]M>>8EC97%S,(S+$B$?
MOD$>XE>>0'_=G_:JQ/J6@I=VDWV>WDDDR;>944[?D>7+'^`85N3W-+>:GX=L
M+>[\Z*W`M[=WF1(,_N^&<#`PW+`D#N<F@!\VN7#^'?[0L[>%[GSDB,+R':I,
M@1LG`((!)P0#ZU2E\:)'8+>K9AH6DEVCSOG,:/L+[0IQDYZX'3)!.*N+<^'[
M>T33'-M'#-(R+#G=N8/C)]#NQR><^])%%X8UR9K6**RNFM@X,:H-H!8AACHP
MW`YZC(]:`(&\6R+<7$:Z5-(%-PD'ER!FF:%@K#:.G4XZ]#QTR+XJ9E$ODP;&
MA1E3SADR-(Z[=Q_W>F-WMQBG:EJGAN.RF\R."Y7S1"\<*`L6FD"$CIU?J<]1
M[5IG0=+,"Q?8XPJX((R&!!)SN'.<LW.<\GUH`QH?&221_:Y;=H+`P0S*Y&YR
M6\W>I7MCRNOOTJU)XF='$']DW1NV8;8=\?W2C/N+;L#A2,>OMS6BFBZ;%LV6
M4*JB*BJ%PH52Q`QTXW-^9HM=$TZR`\BU52"2"S%B/EV]22<8XQT%`%FTN4O;
M."ZB#".:-9%##!P1D9_.IJ9#%'!#'#$@2.-0J*.@`&`*S]7UZRT41).9);J?
M(@M+=-\TQ'7:H].Y.`.Y%`&G17/+-XJU`ADM[#283_SW)N9L<=54JH/7^)JD
MBT763N^T^*+MLMD"&U@C`'/`RC'T[]J`-VBL&71-8#*UMXJODQU6:V@D!_)`
M?UIN?%5@`6&G:M&,Y"!K64\\8R64G'J5H`Z"BLS3-=M-4FEME$MO?0@--:7"
M[)4!.`<="IQ]Y21[UIT`%%%%`')^)G&B>)-&\2,F+4;M/OI/^><<A!1V_P!E
M9%`)[!S769J.>"*ZMY+>XB26&52CQNN593P00>HKSKQMX:O=*\#:I#I>L77V
M%(1Y-E-&9W1PPV+#("'4[MH&=V.U`'I-%>3_``[@^*B)%_;,]LNG#`V:F"]Q
MCV*G/_?9KUB@`K$\,8^PWN,<ZE=_^CGJ;5#KXG3^R$TQH=OS_:WD#;L]MH/&
M*R/#NG>)M&LC:30Z3*CW<L[2+=2Y"R2LY`!CY(W$#D9P.E`'6451N=9TZRU&
MWL+J\B@NKE2T"2G;YF"`0I/!(R..O-7J`"LUM`TII+B0V,6^XF$\K`8+R!-F
MX^^WBM*LC4?$NG:=<-:;I;N^`S]CLXS-+CW4?='NV![T`+-X;TJ>[2YDMVWH
M4(`E<*2@PI*@X)`.!FH-<\-KJNF06=M.+3R4:))`K%E0KM(!#*>F.I(..0:C
M75?$MRR^1X;BMXV_BO;]59?JL:O_`#I@;QL1S%X?!]!),?\`V6@"W#X8T^"%
MX`;AH)(A%)$9F"/A0FX@'[VU1^6>O-2S:!8RW:72>=#,'9F>&4J7#$$JWJ"0
M#_\`K-4VU#Q/;!/-T&SNAC+FTO\`#9]`LB*#_P!]"I;/Q387%V+.ZBN=-O&.
M$@OHO+,G^XV2K_\``230`77AFVN)II?.F+3NGF^8Q?,:OO,:\\`GZ\<#BMNB
MHI[F"UB,MQ-'#&.2\CA0/Q-`$M%16]S!=1"6WFCFC/1XV#`_B*EH`****`"J
M6JZ59ZU8M9WT/F1%@PP2K(P.596'*L#R".:NT4`<Q]NUSPZ!'J%K-K&GJ.+Z
MU4&X0?\`32(?>_WDZX^Z*U=.U_2-6`^PZC;S.>L8<!U]BA^8'V(K2K.U/0-(
MUD#^T=-M;HC[KR1`LOT;J/PH`T:*YT>!]$C""!;^V5`0JP:C<1C'T#XIC>`]
M`EWBYAO+I7()2YOYY5S]&<B@"]J?B?1M(?R[N_C^T$X6WBS+,Q]!&N6/Y5F2
M)KGBD^5+#-HNC$_O%9\7=RO]W*G$*GOR6(_NUNZ=H^F:1&8].L+:T4]?)B"9
M^N.M7:`(+.SMM.LH;.S@2"VA0)'%&,*JCL!4]%%`!1110`4444`%%%%`!111
M0`4444`%9UUHT5UJ<=\\TH=/+P@(V_(6/IGG=SSV'O6C61?V>HRZU:O;RXL7
M`^U?O2&4H2R[1WW$D-TX`H`HQ^$+1+..&UNYEBV[26PQ92CJ>?4^83GU`I)O
M"L5U=W3-J3L7ADAV[5+(LB@`'/88!``'OGK58Z/JZ:;*)XVN[B62!'Q<$D1+
M$H;`+*"?,#'!(SG)STJ2TTS5K3P[J)GF$-]+9HHE$A<JZQ[220,YSW%`RU<>
M%4G,J_;)%BN<B[38/WBF0R84]5Y9AWX/J`:GTOPW;Z3<6\T-Q._D0S0A7(P1
M)*)"3@=01@>U<J+'4-4MI&TP7D>G+<2;(8[@.V3%$%969P"`PDZ,0"<X/;3N
MM#UT///974J7<C2IYTEP2-GD!4^7.!^\`/`'.30(O6WA-;=8(C?2M#:%1:H$
M`,:"59-K'DL?D`SQQ[\UT*.DB[D967)&5.1D<&N*_LC6HK)/)6_DD6=I8X99
ME1$^5<*=LA8*2&.=S$$M\I!Q71:'$T;:FP1TADOG:)7],*&(]BX<_C0!JT44
M4`%<QX41+J^UO4[A5.IF^EM9#U,449Q'&/0%</[ER:Z>L'4]"NAJ+:QH=REK
MJ3*%FCF!:"Z4#"B0#D$=G'(Z'(XH`H>*(?M'B71HFTR34HOLUVS0(ZJ`?W0#
M'<RCN1WZUFR6^LZ'9Z6MK8[[B;5I6M;![KY88V@DPK/S\H(+$#.,X&<"M?\`
MMZ*WNH)]?T:[L+R%619XXVN(0&P6Q(@X!VC[P7I4Z^*?"FH&&?\`MK36:WD+
M1F2X52C;2I."1V8C\:`.>D6.3PB)V\RZU.[U.VCOXYWV%IA,@:(@9"*!P`."
MN#SG)T/#,3?\)7J6+1=*\B!8Y=/68R"4DY2<?P@8#*".2<@XP*L76K^"!-+>
MSZEI+2M+%)(ZW"L6>,_NR0IY(S_+TI\FO6%U>K>:5I5[J=\D9B26*`Q)L8@X
M,LFU2,@'J?:@!OCQ%M]$36(?EU'3IXY+1U^\[,X4Q>X<';CW!["NIKGH-%OM
M2OX-1U^6(FW<2VMA;DF*!^?G9C@R.,\$@`=AGFNAH`YV[\"^'+Z\FN[FP=YY
MG+R,+F5<D^P;`_"HXO`7AJ/<L5G*N#\P6]F'/O\`/6)\0;#XB743GPOJ%HEK
MCF&)?+N3]'8D'\-M5/AA9^)[?P9'&\MK;W(N)OM"7]M*T_F;SR[;QDD8P?3%
M`SJ&\">'F_Y=KH?2_N!_[/3/^%?^'O\`GC??^#.Y_P#CE2W+>*;93*]_H,=N
M@S))+;RJ%&1D_P"LQTSWK,T?6_$FO0R76DW_`(=O;2.0PF5(9U!<`;MIR0P&
M<9%`C;'A;3U4`3:F`!@#^T[C_P"+H_X1:PW9^T:ITZ?VG<8_]#JM_P`5I_U`
M/_(U(Q\;!3M'A\MV!,PH`6;P792NS#4]=C!.=J:M.`..@^:A?!MN@PNLZ_CW
MU24_S-1J_CK/S0^'",'I-..?^^:N";Q1@9LM'S_U^2__`!J@#AO''PNO?$UW
MI-M9ZC<&U@,CSW&H7+3[,[0`BDY)X/<#BNR\(^%9/"VGBUDUS4M3.T#-Y)N5
M,?W!U`_$U)+<>*T7,>FZ/(>>/MTB]O\`KE^%3:7=>(9KMEU72["UMPF0\%ZT
MS%N.,&->.O.:`(?%E]=VFF6]O8RB"YU"ZCLDN",^3O/+@=R%!Q[XJ_I.C6.A
MV0M;"'RT+%W<DL\KGJ[L>68]R:-9TF#6]+EL9RZ!\,DL9P\3J<JZGL58`CZ5
MDQ:_>Z+&(?$UNRK&,?VI;1EK>0?WG49:(^N<KZ-0!@V>M7UQ8VLMKJFI7&JR
M7I4VQM,PL@GVN"=@`4)_%NXP.O0K'XIU2ZUK4=!MY_+N)-5DMH[V6+]W:Q")
M&"KQAY3ERJG/0D\#!ZWP[_9D6D16VE:@E[;PY'FK,LI))).2O&<FJ[>%+&2R
MU2UE>9UU"[-X7#!7ADPH#1D="I0$'UH&8FH>('T[7M3M+[6[JTL[*UMW62.S
M$N2^\,SL$8#)4>@K=TN"?6_"=M%XEL8GGGBQ<02QC!YX)7G!Q@X['Z5-!HT%
MM<WUW<SM<&\MXH;CS@H5@@89(`QSN.>U8UEKVGZ-91:)I<]SX@O;8>6D=MB1
MD7)VB23[BX&!EB"<=":!%*3Q"G@>XU/2K^YDN+6"R-_IQE8M)L&0T!;O@@8)
MYPP!SMS5C^Q[/2]+CUG7;>#5-6G>,2S71W)$9'4;8\@A$4GC`R<<Y)S6CIV@
M37,>HW>O>5)>ZG#]GFBB),<,&"!$I/)^\Q+8Y+'H`!52"XU/1H(--UG2KC4K
M:!E%O?V:^:6"G*&6/[RN,#)4$$\\=*`(9]&CN]+EUG0K5=(UB`LR-;KMCN2A
M/R.`%\R-L8R0",Y&*ZC2[T:GI-E?B,QBY@28(QR5W*#@_G6#?WNJ^(K:;3=,
ML+FP@F'ESW]ZGEE4/WO*3[S/C(!(`!YYZ5T=I:PV-E!:6Z[(((UBC7/15&`/
MR%`$U%%%`!1110`4444`175U;V5N]Q=3Q00)C=)*X51DX&2?>I:Y?QK_`*5'
MHNE<-]NU2`.A_BCC)F;_`-%BNHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"HIK:"Y7;/!'*OHZ!A^M2T4
M`10VT%LNV"".)<YPB!1G\*EHHH`****`"BBB@#B?''PVL_&REI]5U&VE`&Q$
MF+P`CN8CQ^6#5'P;\/+_`$#0FTVYUO4()89G,4UC<XCD1B&SY;A@ISD'@^N>
M:]$HH`Y>1O$^@XE9TU^P4_.HC$5V@SU4#Y),#MA2>V>E;^GZA::KI\%_8SK/
M:SKOCD7H1_0^QY%6:Y73,:#XVO-("E;+5(VU"U'\*S`@3H/KE'QZLU`'5444
M4`%%%%`!1110!CWOA30=0D:2YTFU,K#!E2/8Y_X$N#^M0Q^#M&AC:.*.\CC;
MJB:A<*#^`>MZB@#G8O`GAJ(%6TM9U/\`#=2R3C\G8BMVVM;>SA$-K!%!$.B1
M(%4?@*EHH`****`"BBB@`HHHH`****`"BBLS7M;AT+3_`#W1IKB1O+M;6/[]
MQ*?NHOU[GH!DG@4`9;XU7XBQ`8:'1;-F8_W9Y\`#ZB-6^@<>M=/6-X8T>72-
M*/VQDDU*[D:YOI4Z/,W4#_9484>RBMF@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`K&\1Z+)K%G`]I<"UU*SE%Q9W!7(20`@AAW5E)5AZ'UQ6S10!S]O
MXLLXBMOK:_V/>YVF.Z;$;GU27[KC\<^H!K9AOK2X17ANH9$;[K)("#],5+)&
MDT;1RHKHW!5AD'\*SH_#FAQ2K+'HVG)(C!E=;5`01T(..M`&C)(D4;/(ZHBC
M)9C@#\:Y5?B)H-UXEM-`TRX_M"^N'8,8.8XU499B_0\#HN>?2NCO]/L]4LI+
M._M8KFVE&'BE0,K?@:X6+X/Z!8^*+/6-/39!"6$FGSCS82K*1\@/*D9SW'M0
M!Z&#GI17/#P)X5'30-/'_;$4O_""^%?^@!8?]^10!T%%<^G@?PU&Q,6D019.
M3Y19!^0(I_\`PAV@?\^'_D9__BJ`-VBN=?P-X?>7S/LMPC<?ZN]G0?DK@4H\
M$Z&!Q'??^#*Y_P#CE`'0T5S_`/PA6B?W+[_P97/_`,<JQ8^%]*TZ\CNK9;L2
MIG;YE]/(O(QRK.0>O<4`;%4;K6=-L[VWLKB]A2[N'"0P;LR.<9X4<XP"<]!3
MM4TV+5M/DLYIKF%)!@O;3M$X^C*0:\KT?X1W_A_Q_;ZE!JL\VGLDJ_:DVBZB
M8@D;RP(<')&1STXH`]@HK!DT'4BW[KQ3JD:``;3%;M^IBS4;>'M6<`'Q?JH&
M<_+#;#_VE0!T517-U;V<#3W4\4$2]9)7"J/Q-8K^%S-(C3Z]KD@7^%;L1@_7
M8JFG6_@[P_;R++_9L=Q*O22[=KAA]#(6(Z4`12>*?MS>3X>LI-3D;(%S_J[5
M#ZF4CYOH@8U-I.@/;WG]J:M=?;]692HEV;(X%/5(DYVC@9))8]SV&X````,`
B=!10`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#EAY`("`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````#C`@(`@````%A\L`(EC(^IR^T/HYRTVHNSWKS[#X;B2);F
2B:;JRK;N"\?R3-?VC>=S`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.gif
M1TE&.#=ADP`"`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
A````DP`"`(!8?+`!`@,"#X2/J<OM#Z.<M-J+L]ZV```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.gif
M1TE&.#=A?@`"`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
?````?@`"`(!8?+`!`@,"#82/J<OM#Z.<M-J+<RX`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.gif
M1TE&.#EA8`%5`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````!@`54`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`%D)$DAPH,&""`\J3,APH<)6#AM*C$AQ
MHL6*&"]JS,AQH\>.(#^*#$ERI$E!K;H,1,2*I<N6,%_*C$ESYDM6-`?BM%FS
M)\^?/H,"'2JT*-&C1I,B7:JT*=.G3J-"!<H*`$2!5U$:S,IUJU>L7[6"'2NV
M;%>R9\V&3<MVK5NT;]7"G2NW;ENZ=^W&S<MWKU^\?_4"'BP6@$%$+`4A%KA8
M<>+&C7$23"QY)4&<EC-#?LR9<6?'GD.#'KU9=&G2GT^K3LW:=&O4KF/#GKU:
M=FW:KV_KSLW;=F]!#K,6%!YV^,!`K`(A0JZ<.5B(:8TG)$Y6^L/@V*=GOZZ]
M._?OUL,7_Q]?G7Q9\>73GS=/?;WZ]O"WHW=/O]65S##Q4]X_6:"@0(%<T<45
M!!988"!=``A<3_KUU^"#^47('X032NB@A11>6.&&&G:8X8<8AL@AB".*Z*&)
M))Y8XHJ361586X+<9\455G0QXXTTVICCC0$B(MB/?1$6))`O%BFDD40>J622
M3`[I)))/5O59?I$]AAEP@5BA)8T%:HDCC@3.&&:"/E86&695BD;EA&F.MJ:#
M;<;)YIQPTJF9G6_>6>>>>O:9YY]3!JJFH&X2*B>?@`ZJ*&AE_F@<1(+@*`.7
MDWZIXXR57I$I"P/^1UR434(IZI*@ECIJJ*2>:FJJK)JE4E,Z)?]W*9=B#A@(
MEL#E"J"!7Q)()F863B75L,(62^RQQB:+[++*-EN3BT<B(F"FE<;H(W1:87N5
M<@EB2NF`UZHJ;JNKHFINN>B.>ZZZZ8X%`&7`\I=8C+3.J.!-E^6K4ROS!ABF
M@<I=&*^^$0X<*WX&5U:PP`PCW/#"#D<,\<3P/ERQQ!=33'#&'&_L\<$:@]RQ
MR!\K/+)DC6J;+4J(M')KKU8`I_)S*ZL,W:T"LD"KS#7W;+//0/\L=-!$#VUT
MT4@?K7323"_M=--0/RUUU*_B:QEFL]J[F+,L!>@EC;<R*S;78Y=-]MEFIXTV
M4E4-C16`,ESJ:<M`T]P5MF.]3"F`=Q/_;;=7>/?\]^""%SZSX2L3?OCBB2,>
M.../-PZY6I%73OGE?6<...:;:ZXX2@"P<M5../$KD(YA*M<*Z2R1#JSK^;8>
M>TN1;CGCU::+OF_KH\/TNN^S_RY[K,.CK##LQ!\/?/+"*U\\\L8W+WWPU#-?
M??370Z_]\MA;[WWWX&__//<[L6QSRP!Z>U_4[$.$"(XLW#KU_.W73__]]N>/
M__[Z]\__S2@1G63RDR4NW4>`I1N@['BWP-(U$':MDQ:MY#=`R:RN@J)[8.Y\
MMT$&1J^##OR@!D<HPA*Z#H09-"$'27A"%JY0A1YL(0Q#*,,:OM"&,;RA#G/(
M0QJZZ&>10AU6_^CVOZ*QY$9=D('\_,?$(CJQB5!\HA2C2,56A"YWN8N4@0:"
M10M:,(98!*,8=V)`*R"GBS0,8QK'F,(VJM&-;'RC'.-(QS7:$8YWG&,>ZXC'
M/NK1CWS\HR`#"<8A0B>%ZKL6$1<)'4::[Y'\:J0D(8F3+Y6N9HZ,)"0SR<E)
M:O*3G=RD)T,)RE&:4I2H+&4J2<G*4ZKRE:U<I2MC"<M9FO*,`FS%ZOX5LUSZ
M<G7`_*4P@TG,8?I2B[Y*8`*+R4QC-O.9SHPF-*<IS6I2\YK6S"8VMZG-;G+S
MF]YLF^XBZ34:R:QEZ(PD(]-I/G:JLY3N9*<@=&;&0`"SG?#,YSKU*?_)>+X3
MG_L,:#_Y"="!"K2@"'WG015JT(8F-)T+A:A#&?K0?U+THA*M:,NN:,$8X:AE
MOERF+G\Y4F*6-)<G+>8R!6$C+5'P@M),J>ADJDMFTO2F-LTI275J4IZBU*?`
MQ.E.A]I3HO[4J$$%ZDR56E.D+M6I32VJ5`48P$,*(FXSZL(]MYI!KD9RG%T%
MZU</.=:JHN\*]%2,5T%*5K::=:UP%:M;@3G7L+8UKG>5*U[?JM>^YO6O?`4L
M7?<Z6+\&]K"%%:Q=$;O8Q#*VK*N;!1>;^J\NE*ZDF$WJ4Z.:V<W2E*2L&)"8
M9CK,SG)6LZ?U+&I-R]K5NE:UL$VM;%L;6]K_SO:UMZTM;FW+V]WZ5K?`U:55
M!'B-<EJ!);,08'(CRU:0SJ*YS"WL<Z4+758LEQ77:(FW`I'=Z(9UNM^M+GB_
M.E[GBO>\U$UO>-.;3NNB=[WP)>][Y:M>^L;7O/7%[WV]:U_ZMK>\_-5O?P6,
M7ZL$LX!F#&YO%>Q;:?'HJ+>MJ80GS."E3CBW&%[P:2_,X0YGV,,5]K"&1TSA
M"']8MQ(.<6;)BA,"3<J>RF5KC(LYWAG[LL;\%>8LO&8CG`#8O=Z=;BMP#.0;
MRSC`N@3O<Y-+Y"8?N<A,MJZ4(SGD(U?9I$ZFL96S;&0M>[G+8`XFCJ\<YIDJ
M6<K7):^.MZQ<&U^7_\C7F*S+#&AA$=OYSGA.<4T!EN<^^_G/@`ZTH`=-Z$+G
MN<Z&3K2A`1#E0%2KS:OK+G:)2^E(5WK2ELXTIC<MZ>PF]ZJ:DAFF6R'IZY;Z
MTIU&M:HC>VE3KYK3KW8UJW69:EJ_NM:PUC2N=UUI4M_ZU[H&=JZ'S>M@6SJY
MQ28V=JURC5UR21"S4+2T)^Q1`B%ZVMC.MK:WS>UN;SO:%P:WG5%"ZG)>P=;1
M]K2OTVW==;M;W?!N=[S936]?VYH5+KY/O)O-9%\WV]-H?C=V!5YO=?<[N_\>
M.,+]3?"&+WS>#I>WQ/]-ZH@77.$8OSB[$U[PBC\<XPFG.,<%/G*([YOA'_\O
MN<0WCG*0M[S@*(FV%A/L[4(G%\'D%C$"KWUA"PHZ@SX"3IEXWF%QFTXQN6I)
MH'>^])[>^:<]!V=2.^SS0#\&Z9>],[BOE"NA[\O.C-9EOKD[Y%9@H^S\KGBZ
MT<[VM;M=[7!/N]S;3FK1$HC6-4T[-H!SGRL`*-IO1[B/_'YNCY?]["S'!DYP
M1JD<]5UF<1_RI+N+LP).JE(!@KS(#8]P@?C]N`JG.^(K[K(897[@9\=[L\\N
MK0`%*,F^EI;I"9]YVM>H[SV:Z=SM8WI!=-?L;<=XZ3]/*W.N#_"1OP9+5#(M
M3:$5;'ZW++GG?@UF)^=&,;>ST6NZ?=B'F\/=+_O_A6=^1O&;WSZV\WO1=[DE
MWX,_[[KD>_$)7R`9W.[]-1V\`0'&2[]GG?L7%B9F)&'AMWVAI2FW8V8<AF];
M<A^D%W]=,G_.]R__DG/F%V?U9T_A1X#Z9W\&(B!BHBD:"(!)]A_Y=B`)TG\.
M^'W0)G8YXGZ;%X.<-X,R6(,T2(,LI3.%MWJ<YR/T]'P[:'A[YV@T(CIG%X,#
M9Q\39$]5I14Q8H0W*%F!0$\!HG2Y)']I!8,>AWK`,2,L,!`R>(3`1W%*6"TP
MB''X-H&Z=(1)6!P4^#>VMGFM@"-=L'EBV&PN,X70]QQT(WM:*'+_0866=63'
M$2/`<8<5MW>^1F?X-V$%_]B(!`B))%AV:3@C23AA>-A_+A6)X+9%:>=]E$B!
MDR6'\+=]LR!S!C2*,P@1$W2)>+=G7&)/YO>($V9<]H2'92=!H_6`R+=V%(=S
M-]AARK<SCGAAQC6*L_!OR0A_D=AL!40@+2ARRWAAN"AA`)!ZF*(<8KB-B=B-
M//B-8QB.W`B.XRB.+'4C:^B-9O<?U:(^>'=VV+`<]"0ZY$AZ%)B.=@A\Y7B$
M@6A.K`"/;,>#.V9Y`X&(1^@CEP>&XJB.W%B&H89ZJ^..,UB.F>A\9%>/]3B'
ML4AQ#8D@E<(2&-F-Y3@+2%1X%,F0(LEL]')WYI=Z#XB+,,F,+RF3,?F*,UEV
M6_^T=C:IA`(B?_8B815Y.RY9D]5V!2U#AC>9E,U&+[>S>S<I@%<@.H&G2Z(U
M@#1YE3KI-5H"ALGU-5K%BU>)=W(SDSKY@'M'C+B(?!B8.F0YC4I9=K5C+_0X
M9,M8EC59<>[7"I@G"`#9E_KXEWX9F(`YF()9F/+(DH4I$//H;),2A$.(*5`8
MF/_AA<A1F(0YF$HH)NEHF8HW<W['@WVY'%Z($HH'FI?IETJ85I4$A)MYF:9Y
M#?]"=ISYEQII+Z8)D/,$-G\XF+<)F`+A+3&#'`&47+,)CZ3)@'=W#>"X>;Z8
M?,Y)?<\9D!67AM9VDIEY'V?'E.IGC\]F@\CTF<O8FP+_28/7!S;=J'H>EXS5
M%C/AJ(SHMXGA.8/-N7OFYB^:&9_0*8/`*(;S&9#(R9X4MW:5."/H:8,&JDM:
M^34"<BO3%Y_1)H;7Z()QPY>G6:'%::$8NG=)A)B$>9A6`(5:I(/L!FH?ZIH!
M\I$96J'7>04<6:&L`":M"8^*&6HI:IEYF"F:6:-_"9NQ>*$`>9V!4)B3F425
MJ:.<R7<;ZH70YRFG:15GUR78Y9*C=X2S,*6D5J6'=Z56>@U8^J!:FJ5<NJ79
M-2:D=@WCV&RIJ)S9*8`C:'>(<*;9B2-Y.898^HU=.H9FNI(#.(YU.H8>M95E
M.I0(2B-FI'?>>*=4BHAS1H>D_[:EB/JE7KJ?D$JGB4J=['FF#*B9RHF2&%FG
M9CIDGWIT_^$OHGBHV7F$8T*A/FJDK"J97:"#O2FCN5FBLJJD+"H0E1*C^GB.
M:$6:K0I\M4DCC8JA+VJ1L?J;O?JKJ'F/RDIJL;FJV-BCA)D<5*BJS6JCNJ-%
ME1*9NPI\,X<2H-FG?BF>O%FNXTJIW?BMYAIM%?AOGZJ=]I0E0OFI`,FEBYJ<
M82B26%JO$"&GRKF<>(J!8N*K]8JF!S*LA2FN.PI\"&9/B2J2"VF:DGJN@8F<
M#BB8K#BP.@JP+0J/9OJQ2PF59:J/U0>/`_)BT'JMK5I9G/F;242PWJH^,Z>K
M/PHF8?^JK/TH`S";F-IZB-,*:E^HLO#(K"E;K\^JH]=IK<MJ0#0KM+XYA4ED
M68'II/UJGO"(#1Y[A/3ZJ6IJ=ER[M5J;M8'JM6$[MF?WC/1(KUCKM3SYF6O;
MM=I9@6)KIKCY-;>(#?^*MUBKMVNKMV0;LNUG=F_[L7O+BL]6MF%JL/.ZMXQ+
MMW,+MC%KM9#;M7Y+N9^*<Y[ZN%G[G[YWA'W[L95H;8VJMX3;MX-[M?Q6NF$+
MNEY2(\.JIMFEM^O9M$7KM#6K*5WPIA5*HCN+I6GX@S(0I;N+HR")F5QDF7&F
MAS'C?O!8I\"A,SK#E_3JFR$*AA/'<!?*H[!ZK4?KH\TFI[/_F9K02&[C:A""
M&6=/")'UBH4<VI>D^:2'^[G84*5F2K_SJ[?VF[_XN[_UR[_WV[^J6Y2-:K]_
MF[2D.[]=&[J+:[^$^[%S)HI=AR!A0IH$_+_999_CVW5Q6Y"$6Z582[^9J26V
M4B`#8B`#[+\$W+!D6Z7Z"\#_"Y#[Z<(M[+?$Z+?^&[(4R*!8@L&(0+<@&R.9
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M-KRO^VK%WGR_@$G/-<K/\FS#WPR8[DRVIUG,DDG`GFG+?/O*DOS*#OW0$!W1
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MS)[YCVR]V@^]GN_+VK`=V[(]V[1=V[9]V[B]MU&]O^6IL_^HNH:,U),-RHXM
MVL(MHT382XB-U)]-VL0-VJ+MW(0]W,4-W9<MW=?]W,X]W-1MW=O_7=FE'=ZA
M[=WC_=W8;=[8L-NO[-H*G=L1;;A"Z=[R/=_T7=_V?=^KO=A]RTO6'-R=#=[_
MO=@04=>;;="J^\D%#N!YG<[<K>"@[=DO+-X&KM<*K=\.CMX);N$:SM@!KMT=
MCL@(;MKO_8%1BM]X&[?M+=>L;(0W#1UAO3H:;,TD'7^L'',F#>.D/+HT3>-=
ME^(JKM#HZ^.T[>(M+C-9_=HWSLHIKM[*'*Q68,HF#=-2WM:?6JR:BM99O;?T
M@C=^=]I<'=/9^84LS;9"S.6W$LK8G-7042#00;8J/;\$PH2'U-8S?<5&N3+C
M3=+0&,JAQ0*"&]<1/>5]?99!.NAZCE9G__ZN?F[H'5WEZZ,M^LBX3,[0<<OB
M]`W?U@;H#ZV750V7V$G3AMCBT"C)!NOE8YXE0C[BY\:U6+WE8'W5<V:$H$O(
M\GU52*[B]'?:Q?7I(KWE8+[I>WO<<UVLC?G:%A[BR+[7[[HIF^G0Q[W1#I8K
M*J'<(/[8\Z3:SM[:!$+J84ZPC&[A>TZX*8[-/"GM@CONH1PCBZ[((9[BC5P@
MR4$08=+("XWNW][69&MZ6/[L>SOJ<;ZF_;WI2NCE[:[E)"U98.*P[EV>`ZOI
M$#WP66&(J;[>O&[2Q9KB!>3PA7OM6)T2ZX,5$Y_5M,[:K,A%5#7RN1TIIB[6
M3SC5`A+K-X[R'/\]Z9MNY:'6N;?=CS=BA/0.Z@1RP.I^ZQ;=[44>M`L-Q#)>
MUOU>\2+]P=59VH`^X!R\US>]YWVK[G]^VWGJ=U=M]6=I1NM.TB6\>GV[Y"^M
MP)D^VXK+M!K_\-`(*7PG]!$=ZD7^Z`:1>3T_XY$2\@[M\3P#\CMNB+="-W(O
MT:Q8X3*?\_H6^!>+R?%KTG%/;E@![&/ND-CG>R%][UC+[\K9A<^GF8A\TZ%:
M,S-%]<"^\F.NB-D2Z5_>]Z+,^C.>>I#$]X4L^]AB^H;?[+)_Z4D_XTD??ZW_
MWI#>^WL'Z^O)B&WOM]H9@CAOXL[__-`?_=*_VC1/TC["(Y=7A<S[M^O_BV]$
MB%7F]*:,+OHE'=NT'_Q#/_VAK_[LG_KS7?TS3IV$FO`J81"Z@L$WTH"6WO[\
MW__^__\`@4W@0((%#19L=5!A0H$,L0D2=.4*BRM6KLBH>#$C1HX;,UJ!B,VA
M0X+2%!YT.&O@R)4G7;X4V;*AS)@P9]ZT29`D39@L<>8TZ+,F4*)%$=+<F5.H
M0D%&@[82%$BB1:H?*UJI:O%*($&MDCH%&U;L6+)ES9Y%FQ8M@+->(6ZMVI&B
M%:D0O:K%FU?O7KY]_>IEFW:65Z@0#1MFE?#K7\:-'3^&'-GE8J"N!EZ[C)3G
M0,N2/7\&'5JTS::C39]&G5IUVL",5:Z&'5OV<FR;K6G?QIU;-UK*1C'C?(WM
MM_"!P;\.1[Z[I'+FS0F6=AY=^O38MJE?QY[=L77MW;U_)]L*``"HX\N3%V0^
M/7KU[=F_/Q]_O7SW].'/QU\__WW]_?G_MR_`_03TCT``!T2PP`0/5+!!!A\T
),,(%([PB(``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>9
<FILENAME>v384723_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &quot;Auditor&quot;
in the Registration Statement on Form F-10 and related base shelf prospectus of Oncolytics Biotech Inc. (&ldquo;Oncolytics&rdquo;)
for the registration of Common Shares, Subscription Receipts, Warrants and Units, up to an aggregate initial offering price of
Cdn. $150,000,000 and to the incorporation by reference therein of our report dated March 12, 2014, with respect to the consolidated
financial statements of Oncolytics, and the effectiveness of internal control over financial reporting of Oncolytics included in
its Annual Report (Form 20-F) for the year ended December 31, 2013, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Calgary, Canada</FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Signed &ldquo;Ernst &amp; Young LLP&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">July 25, 2014</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chartered Accountants</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>10
<FILENAME>v384723_ex5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 25, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oncolytics Biotech Inc.<BR>
210, 1167 Kensington Crescent N.W.<BR>
Calgary, AB T2N 1X7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>Re:</B></TD><TD STYLE="text-align: justify"><B>Registration Statement on Form&nbsp;F-10</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the reference to us
in the registration statement on Form F-10 (the &quot;<B>Registration Statement</B>&rdquo;) and the related preliminary short form
base shelf prospectus (the &quot;<B>Prospectus</B>&rdquo;) of Oncolytics Biotech Inc. (the &ldquo;<B>Corporation</B>&rdquo;) relating
to the registration of Cdn.$150,000,000 of common shares, subscription receipts, warrants, and units of the Corporation. We also
consent to the use of our firm name in the Prospectus under the headings &ldquo;Enforceability of Civil Liabilities&rdquo; and
&ldquo;Legal Matters&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In giving this consent, we do not thereby
admit that we come within the category of persons whose consent is required by the Securities Act of 1933 or the rules and regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>/s/ McCarthy Tetrault LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">McCarthy Tetrault LLP</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
